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ABSTRACT
The use of recombinant gene expression for industrial protein production has 
since the early 1970s become a multi-billion industry. Despite many years of intensive 
research, no universal expression system exists that can be used for high-level industrial 
production of any given recombinant gene. Because of this, much work must be done 
prior to production to identify the ideal production organism for the gene of interest, 
usually followed by optimization of an expression system useful in this organism. 
One of the most popular production organisms is the gram-negative bacterium 
Escherichia coli, which is regularly used for high-level production of both prokaryotic 
and eukaryotic proteins. Despite its popularity there are some well-known drawbacks of 
using E. coli for recombinant expression, including lack of some post-translational 
modifications of recombinant proteins, and few and inefficient systems for translocation 
and secretion. 
In the present work selected key processes in E. coli recombinant protein 
production has been studied with focus on exploring methods to improve protein 
production in this organism. The key processes include the use of signal peptides for 
efficient translocation of eukaryotic proteins to the periplasm, directed evolution of the 
transcription regulators for increased expression from their cognate promoters, and the 
use of codon-optimized synthetic genes. 
The use of signal peptides to achieve efficient translocation of recombinant genes 
is a well-known and common method. By testing the signal peptides sequences ompA, 
pelB and the novel, designed consensus signal peptide sequence CSP, in combination 
with the eukaryotic cDNA for the proteins hGM-CSF, scFv-phOx and hIFN-α2b, it was 
shown that the effect of signal peptides are gene-specific and, more importantly, that the 
presence of signal peptides not only directs the gene products to the periplasm but also 
increases the expression of the recombinant genes. Under high cell density culture 
(HCDC) expression production volumes of 2.3, 1.7 and 0.6 g/L of scFv-phOx, hGM-CSF 
and hIFN-α2b, respectively, were obtained. 
The use of directed evolution on transcription regulators featured in expression 
systems is a novel approach for improving recombinant protein production. By evolving 
the transcriptional activator XylS with error-prone PCR and subsequent DNA shuffling it 
was possible to obtain evolved activators that increased induced expression from their 
cognate promoter Pm at least 10-fold, both with the prokaryotic bla gene and the 
eukaryotic gene for the antibody fragment scFv-phOx as reporters. The basal expression 
only increased about four-fold, and hence the induction ratio was increased. By 
predicting the 3D structure of the N-terminal of XylS it was shown that the obtained 
substitutions were positioned in different structural sub-domains. Based on this it was 
proposed that the substitutions probably affect different functions of XylS. 
By analyzing xylS mutants that caused both high induced and basal levels of 
expression from Pm, the mutation G33A was shown to form a new promoter reverse 
oriented within the coding region of xylS. This novel promoter is the origin of a transcript 
that traverses the more than 800 base pair region between the xylS gene and the bla gene, 
resulting in increased amounts of bla transcripts available for translation and an apparent, 
though false, increase in transcription from Pm.  
In order to produce XylS in large quantities for structural studies it was 
discovered that the xylS gene contains unfavorable codons that may limit its expression in 
E. coli. To circumvent this problem, a synthetic de novo version of the xylS gene, syn-
xylS, was prepared. syn-xylS was in silico optimized to give optimal translation of its 
corresponding mRNA in E. coli, containing only frequently used codons and forming no 
known mRNA secondary structures that would inhibit translation. Surprisingly, the 
translation of syn-xylS was significantly reduced due to changes in the 5’ region of the 
gene (relative to wild type), with a single change in position 42 (C42) alone being able 
to cause the entire reduction. 
The findings presented in this work contribute to our overall understanding of 
recombinant expression and open up possibilities for development of improved 
expression systems useful for industrial scale protein production. Although the focus of 
this work has been the optimization of recombinant expression systems in E. coli, the 
results presented are generally applicable to other bacterial production organisms and can 
potentially be used to improve any such system, probably including eukaryotic 
expression systems. In addition the findings expand our understanding of the specific 
Pm/xylS expression system. Although the work has been done in E. coli, this system is 
known to function in many organisms and the findings can hence be used for 
improvement of broad-host-range applications.    
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1. INTRODUCTION 
1.1. Recombinant protein production 
In 1973 Stanley Cohen and Herbert Boyer pioneered the use of recombinant DNA 
technology for cloning and expression of genes in foreign organisms. They cloned DNA 
from the Salmonella typhimurium streptomycin resistance plasmid RSF1010 into the 
Escherichia coli plasmid pSC101 and observed tolerance to streptomycin among the 
transformants (Cohen et al. 1973). The first reported production of a human recombinant 
protein took place a few years later when the then newly started biotech company 
Genentech announced that they had managed to express the gene encoding human 
somatostatin in E. coli (Itakura et al. 1977). The value of the resulting bioactive substance 
was similar to that of somatostatin extracted from the brains of 500.000 sheep. In 1982 
Genentech followed up this success with the product humulin, a recombinant insulin 
produced in E. coli and the first recombinant biotech drug to be accepted for market by 
the Food and Drug Administration. Today the production of recombinant proteins has 
become a huge global industry with an annual market volume exceeding $50 billion 
(Schmidt 2004).
At the start of the recombinant protein expression era the bacteria Escherichia coli
and Bacillus spp. dominated as hosts for recombinant expression, but the realization that 
a protein may require a specific host physiology and biochemistry for optimal production 
stimulated a search for new hosts, both prokaryotic and eukaryotic. Parallel to this quest, 
recombinant DNA technology advanced tremendously thereby opening up possibilities 
for the use of novel organisms. As a consequence, many different expression systems for 
use in many different hosts are now available, including systems for use in yeasts 
(Gellissen et al. 2005), filamentous fungi (Nevalainen et al. 2005), insect and animal cell 
cultures (Wurm 2004; Kost et al. 2005), gram-positive bacteria like Bacillus (Westers et 
al. 2004) and Streptomyces (Binnie et al. 1997), and gram-negative bacteria like 
Escherichia coli (Jana and Deb 2005). Success in gene expression projects is therefore 
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both a question of identifying the optimal host for the specific gene and then choosing 
and optimizing an expression system in this host. 
1.1.1. Recombinant protein production in gram-negative bacteria, with 
focus on Escherichia coli
Bacterial expression systems are the preferred choice for production of many 
prokaryotic and eukaryotic proteins. The reasons for this lie in the cost-effectiveness of 
bacteria, their well-characterized genetics, and the availability of many different bacterial 
expression systems. Among the hosts available for recombinant expression, Escherichia 
coli is in an exceptional position. This stems from the many decades of intense research 
on its genetics as well as the broad scope of biotechnological tools available for genetic 
engineering of this organism. As a host for recombinant expression, E. coli is especially 
valued because of its rapid growth rate, capacity for continuous fermentation, low media 
costs and achievable high expression levels (Yin et al. 2007). One consequence of this 
popularity is that about 80% of all proteins used to solve three-dimensional structures 
submitted to the protein data bank (PDB) in 2003 were prepared in E. coli (Sørensen and 
Mortensen 2005) and during 2003 and 2006, nine out of 31 approved therapeutic proteins 
were produced in E. coli (Walsh 2006), among them important growth factors, insulins 
and interferons (Schmidt 2004). 
The major drawbacks of using E. coli for recombinant protein production are its 
lack of secretion systems for efficient release of proteins to the growth medium, limited 
ability to facilitate extensive disulfide-bond formation and other posttranslational 
modifications, inefficient cleavage of the amino terminal methionine which can result in 
lowered protein stability and increased immunogenicity, and occasional poor folding due 
to lack of specific molecular chaperones (Makrides 1996; Yin et al. 2007). 
Most expression systems for E. coli are plasmid-based. This ensures, in most 
cases, a relatively easy cloning of the recombinant gene into the host cell (no 
chromosomal integration of the recombinant gene is necessary) and it facilitates many 
copies of the gene in a single cell. On the other hand, recombinant gene expression from 
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plasmids demands high plasmid stability which is often achieved by the use of antibiotic 
resistance markers. This represents a potential problem when the produced protein are to 
be used for therapeutic purposes since any traces of antibiotics, especially β-lactams, may 
cause allergic reactions among patients (Williams et al. 1998; Swartz 2001). In addition 
there is the potential possibility for transfer of drug resistance to environmental 
organisms, with especial concern for pathogens (Williams et al. 1998). 
The most popular commercial expression system for E. coli is the Novagen pET 
expression system based on the T7 promoter (Yin et al. 2007). It represents more than 
90% of the 2003 PDB protein preparation systems (Sørensen and Mortensen 2005). The 
pET system was first described in 1990, and has been developed for a variety of 
expression applications (Studier et al. 1990; Dubendorff and Studier 1991). Other popular 
E. coli expression systems include the Invitrogen pBAD system based on the arabinose 
operon promoter (PBAD), the Amersham Biosciences pGEX system based on the tac
promoter, and the Qiagen pQE system based on the lac/T5 promoter. 
Gram-negative alternatives to E. coli include the Ralstonia eutrophus system 
which has been reported to be useful for high-level production of the soluble protein 
organophospohydrolase caused by its low inclusion body forming tendencies (Srinivasan 
et al. 2002; Srinivasan et al. 2003), the Caulobacter crescentus system which is 
promising for high-level secretion of many recombinant proteins (Umelo-Njaka et al. 
2001), and Pseudomonas fluorescens which has been used for high-level production of α-
amylase (Landry et al. 2003). 
1.2. Maximizing recombinant protein production in Escherichia coli
Despite all the recombinant expression technology that is available for E. coli, 
successful protein production in this organism still frequently relies on carefully choosing 
and optimizing the expression system for the gene of interest. There is no single system 
available that is optimal for any given recombinant gene. The most important approaches 
to maximize recombinant protein production in E. coli involve choosing or designing the 
optimal promoter, engineering the transcription regulator, adjusting the recombinant gene 
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copy number, engineering the 5’ untranslated region, increasing messenger RNA 
longevity, transport to specific cellular compartments, choosing and designing the ideal 
production host, and optimization of fermentation conditions (Makrides 1996; Baneyx 
1999; Schumann and Ferreira 2004; Jana and Deb 2005; Sørensen and Mortensen 2005; 
Choi et al. 2006; Terpe 2006). All these approaches will be discusse in the following 
chapters. Downstream processes, including purification and refolding of inclusions 
bodies, will not be covered. 
Although this is written with E. coli in mind, the presented topics are in general 
applicable to other bacteria while restrictions in available genetic tools as well as 
fundamental differences in physiology and biochemistry between the organisms, may 
limit their relevance. 
1.2.1. Choosing and designing the optimal promoter 
1.2.1.1. Promoter structure and transcription initiation 
The promoter is an important target for increasing recombinant protein production 
because of its role in controlling the transcription initiation of associated genes. The 
promoter consists of DNA sequences crucial for recognition by the RNA polymerase. In 
E. coli these sequences are compromised by the core sequences, usually centered around 
positions -10 and -35, an extended -10 element and occasionally a UP element (Browning 
and Busby 2004). Consensus sequences for the σ70-recognized -35 and -10 sequences in 
E. coli are shown in Table 1. 
Transcription initiation requires that the core RNA polymerase (consisting of the 
subunits ββ’α2ω) associates with a specific σ initiation factors to form the holoenzyme. 
The holoenzyme will bind promoters differentially as specified by its σ factor. E. coli
encodes in total seven different σ factors. The predominant σ70 is responsible for 
controlling transcription of the housekeeping genes whereas the six alternative factors are 
required for transcription of smaller subsets of promoters (Gruber and Gross 2003). The 
association between the holoenzyme and the promoter is stabilized by the differentiating 
contacts between the σ factor and the core sequences of the target promoter and the 
INTRODUCTION 
5 
extended -10 element, and contacts between the α subunit and the UP element (Wösten 
1998). Subsequent unwinding of the duplex DNA from approximately the -10 to the +2 
position facilitates contact between the template strand and the active site of the RNA 
polymerase essential for the following mRNA synthesis (de Haseth et al. 1998; Tomsic et 
al. 2001; Tsujikawa et al. 2002). The initiation step is characterized by many rounds of 
abortive synthesis, but once the RNA polymerase has synthesized a polynucleotide of 13-
15 base pairs length, the transcription complex undergoes promoter clearance and the 
elongation step begins (Carpousis and Gralla 1980; Krummel and Chamberlin 1989; Hsu 
et al. 2003). 
Table 1: DNA sequences of some promoters used in Escherichia coli expression vectors recognized by 
the housekeeping sigma factor σ70
Promoter -35 region Spacer -10 region 
lac TTtACA 18 bp TATgtT 
lacUV5 TTtACA 18 bp TATAAT 
trp TTGACA 17 bp TtaAcT 
tac TTGACA 17 bp TATAAT 
trc TTGACA 18 bp TATAAT 
λ PL TTGACA 17 bp gATAcT 
λ PR TTGACt 17 bp gATAAT 
lacI gcGcaA 17 bp cATgAT 
lacIq gTGcaA 17 bp cATgAT 
lacIq1 TTGACA 18 bp cATgAT 
Consensus TTGACA 17 bp TATAAT 
1.2.1.2. Promoters suitable for recombinant expression and their features  
A promoter used for recombinant protein production should primarily give 
enough mRNA so that its level is not the limiting factor for the overall protein yield (i.e. 
it should be strong). Still, an increase in mRNA may not lead to more recombinant 
protein if other parts are limiting, e.g. if the translation machinery already works at 
maximum capacity. Secondly, the promoter should be controllable since constitutive 
promoters will not allow efficient production of toxic proteins and even some native 
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proteins which are deleterious to the cell when over-expressed. One example is 
membrane proteins which when overproduced may cause cell death (O'Connor and 
Timmis 1987), possibly by jamming the inner membrane (Schumann and Ferreira 2004). 
Thirdly, promoters used for recombinant expression should have a low basal transcription 
rate (i.e. they should have low leakage). The low leakage reduces pre-induction strain on 
the host from the metabolic burden of recombinant protein production and expression of 
host-toxic proteins. 
Some of the most commonly used promoters for recombinant protein production 
in E. coli are presented in Table 2. A few key promoters will be discussed with emphasis 
on how they have been optimized through rational engineering for maximized protein 
production. 
Table 2: Examples of commonly used promoters for recombinant expression in E. coli
Promoter Regulators Inductiona Original reference 
lac LacI, LacIts IPTG, thermal (Gronenborn 1976) 
trc and tac LacI, LacIts  IPTG, thermal (Brosius et al. 1985) 
λP
L
λcIts 857 Thermal (Elvin et al. 1990) 
T7 LacI, LacIts ITPG, thermal (Studier and Moffatt 1986) 
phoA PhoB, PhoR  Phosphate starvation (Miyake et al. 1985) 
PBAD AraC L-arabinose (Guzman et al. 1995) 
cspA unknown Thermal (Mujacic et al. 1999) 
rhaP
BAD
RhaR, RhaS L-rhamnose (Haldimann et al. 1998) 
tetA TetR Tetracyclin (Skerra 1994) 
Pm XylS m-toluic acid (Blatny et al. 1997) 
aIPTG: Isopropyl-β-D-thiogalactoside 
1.2.1.3. The lac promoter and its derivatives 
One of the earliest operons to be studied in detail was the E. coli lactose 
utilization operon (the lac operon), and the classic model of gene regulation by Jacob and 
Monod was based on its properties (Jacob and Monod 1961). Hence, the lac operator 
with its repressor, LacI, were quickly adopted for use in recombinant expression (Polisky 
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Bonehi et al. 1998). Attempts at circumventing the all-or-nothing phenomenon for PBAD
have resulted in host strains with engineered transporter systems for L-arabinose 
(Khlebnikov et al. 2000) or with systems for facilitated diffused transport of L-arabinose 
(Morgan-Kiss et al. 2002).
1.2.1.6. Randomized engineering of promoters 
In addition to the aforementioned examples of rational engineering of promoters 
for improved recombinant expression, the engineering of promoters through the process 
of randomized engineering has gained recent popularity. One example of randomized 
engineering of promoters is the construction of a library of synthetic stationary-phase and 
stress promoters, recognized by σ38, based on randomization of the sequence in the -37 to 
-14 region in a set of such promoters (Miksch et al. 2005). The resulting promoters 
exhibited activities (measured in specific fluorescence units, sFU) from 670 to 13,380 
with the strongest synthetic promoters having a three- to four-fold higher activity than the 
natural promoters which were used as references. 
Another recent example is the construction of a promoter mutant library based on 
randomization of a E. coli consensus promoter sequence (de Mey et al. 2007). In this 
study the -35 and -10 region were kept constant and the flanking regions were 
randomized. The activity of isolated promoters varied tremendously, from 27.5 fold 
higher than the lac promoter, to almost 7 fold lower. 
1.2.3. Engineering transcription regulators 
1.2.3.1. Modifying the expression of transcription regulators 
Another potential target for maximizing recombinant gene transcription in E. coli
is the transcription regulator which together with the promoter controls the crucial step of 
transcription initiation. This can be achieved either by engineering its function or 
adjusting its expression. The latter has been demonstrated with the reduction of lac
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promoter leakiness through increase of LacI expression. One example is the PlacIq
mutant which contains a C → T mutation in the -35 region leading to 5-10-fold increase in 
intracellular LacI concentration (Müller-Hill et al. 1968; Calos 1978) (Table 2). The lacI 
gene under transcriptional control of PlacIq mutant integrated in the host’s chromosome 
is sufficient to efficiently repress transcription on medium-copy number plasmids 
(Baneyx 1999). For repression of recombinant expression from high-copy number 
plasmids, the lacI gene with PlacIq is typically cloned onto the plasmid itself, or provided 
in trans from a second plasmid (Baneyx 1999). Another PlacI mutant is PlacIq1 for which 
the entire -35 region is exchanged with the consensus sequence for σ70-dependent 
promoters (Table 2). The resulting promoter is 170-times stronger than PlacI and can be 
integrated on the host chromosome and still efficiently repress expression from high-copy 
number plasmids (Glascock and Weickert 1998).  
Another example of transcription regulator expression optimization comes from 
the transcription activator XylS. By over-expressing XylS from the strong tac or tet
promoters, and hence increase its intracellular concentration, the basal transcription from 
its cognate Pm promoter has been shown to be increased substantially (Inouye et al. 1987; 
Mermod et al. 1987; Spooner et al. 1987). There is an equilibrium between active XylS 
(which stimulates transcription) and inactive XylS. Higher production of XylS in the 
absence of effectors will thus result in more inactive XylS proteins, but because of the 
equilibrium also more active XylS proteins. The role of effector molecules are to shift 
this equilibrium towards more active XylS (Inouye et al. 1981; Franklin et al. 1983; 
Ramos et al. 1986; Mermod et al. 1987; Ramos et al. 1987; Marqués et al. 1994).  
1.2.3.2. Optimizing the function of transcription regulators 
Another approach for optimizing expression of recombinant genes is to engineer 
the function of the transcription regulator. Again lacI provides an example with the gene 
mutants lacIts and lacIqts which encode the temperature sensitive LacIts repressor. LacIts 
can be used to evade the need for chemical induction of lac-based promoters (Bukrinsky 
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et al. 1988; Hasan and Szybalski 1995). LacIts contains a glycine to serine substitution at 
position 187 and full induction is achieved at 42°C (Hasan and Szybalski 1995).  
 Efforts have also been made to create structural XylS mutant proteins which are 
more efficient at stimulating transcription from Pm in the presence of different inducers 
(Ramos et al. 1986; Ramos et al. 1990; Michán et al. 1992). A mutation in XylS which 
increases its ability to stimulate transcription from Pm in the presence of its most potent 
effector, m-toluic acid, the R45T mutation, has also been documented (Michán et al. 
1992). 
Systems that utilize two promoters for the simultaneous expression of two 
recombinant proteins are sometimes desired, and in such cases independent control of 
each promoter may be important. It has been shown that IPTG is an inhibitor of AraC, 
thus rendering the simultaneous use of PBAD and lac-based promoters impractical (Lee et 
al. 2007). To overcome this problem directed evolution of AraC was initiated with the 
goal to obtain an AraC mutant protein which is not inhibited by IPTG. This resulted in 
the isolation of an AraC mutant protein that was able to stimulate transcription from PBAD
in the presence of 2.5 mM IPTG at approximately the same level as parental AraC in the 
absence of IPTG (Lee et al. 2007). 
1.2.3. Adjusting the gene copy number 
The copy number of the expression vector is an important parameter for 
optimizing recombinant expression. This number is determined by the specific origin of 
replication and sometimes associated cis acting elements like rep proteins (del Solar et al. 
1998). It is also affected by plasmid and host genetics and cultivation conditions such as 
growth rates, media and temperature (del Solar et al. 1998). Most commercial expression 
vectors are based on replicons with moderate copy numbers (15-60 copies per cell) 
(Baneyx 1999; Jana and Deb 2005) and thus it is often possible to achieve an increase in 
recombinant protein expression by increasing the expression vector’s copy number and 
hence the copy number of the recombinant gene.  
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Increase of plasmid copy numbers should be used with caution since many studies 
have shown that the metabolic burden on the host cell from elevated copy numbers can be 
detrimental to the host cells (Bentley et al. 1990; Birnbaum and Bailey 1991). It is also 
known that high-copy vectors may suffer from segregational and structural instability 
(Jones and Melling 1984; O'Connor et al. 1989). Segregational instability is defined as 
the loss of plasmid from one of the daughter cells during division because of defective 
partitioning. Structural instability is attributed to deletions, insertions and rearrangements 
in the plasmid structure, resulting in the loss of the desired gene function (Rai and Padh 
2001).
1.2.3.1. Adjusting plasmid copy-number by engineering ColE1 type replication  
The majority of vectors used for recombinant expression replicate by replicons 
derived from naturally occurring plasmids of the ColE1 type (Sørensen and Mortensen 
2005). The ColE1 replicon featured in the majority of expression vectors is derived from 
the pBR322 plasmid (Bolivar et al. 1977) which has a copy number of 15-20 per cell 
(Muesing et al. 1981; Lin-Chao and Bremer 1986; Lee et al. 2006). Replication of ColE1-
type replicons are initiated by the replicator primer RNA II which hybridizes to the 
replication origin and, upon cleavage by RNase H to release the 3’OH, is elongated by 
the E. coli DNA polymerase I (Tomizawa et al. 1974; Tomizawa et al. 1975). Cleavage of 
RNA II is inhibited by prior hybridization with antisense RNA I (Tomizawa 1984; Hjalt 
and Wagner 1992). The interaction between RNA II and RNA I is stabilized by dimers of 
the Rop (Rom) protein (Tomizawa and Som 1984; Brenner and Tomizawa 1989; 
Castagnoli et al. 1989) (Figure 4). 
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1.2.3.3. Benefits from use of chromosomal integration and very-low copy number 
plasmids 
Some of the problems observed with elevated copy numbers may be magnified 
problems arising from the general presence of plasmids inside the host. Many studies 
have focused on the effects of plasmids on the host cell and demonstrated perturbations in 
normal replication, transcription and translation, changes in nutrient uptake and decreased 
growth rates (Diaz Ricci and Hernández 2000; Grabherr and Bayer 2002; Grabherr et al. 
2002). A recent study showed that key pathways like glycolysis, the tricarboxylic acid 
cycle and the pentose phosphate pathway are perturbed by the presence of both low (50 
copies per cell) and high (400 copies per cell) copy number plasmids (Wang et al. 2006). 
Thus, in some cases very-low copy number plasmids are desired (Jones and Keasling 
1998), an example of which is the pETcoco vector (Novagen) which has a copy number 
of one per cell. A completely different strategy is chromosomal integration of expression 
cassettes featuring the recombinant gene and the systems necessary for recombinant 
expression (Olson et al. 1998) (Jana and Deb 2005).  
In addition to circumventing problems emerging from the presence of plasmids in 
the cell, very-low copy vectors and chromosomal integration usually eliminate the need 
for antibiotics selection markers as discussed in Chapter 1.1.1.  
1.2.4. Increasing messenger RNA longevity 
 Degradation of messenger RNA is an important regulatory mechanism limiting 
the number of times a messenger can be translated into a protein. This form of regulation 
of gene expression is important in virtually all organisms (Hall et al. 1982; Marcaida et al. 
2006). In E. coli the average messenger decays with a half-life of about five minutes, but 
the half-life of individual messengers can be as short as a few seconds or as long as an 
hour (Baumeister et al. 1991; Bernstein et al. 2002). A wide array of enzymes is 
responsible for the degradation including the endonucleases RNase E, RNase K and 
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RNase III, as well as the 3’ exonucleases RNase II and polynucleotide phosphorylase 
(PNPase) (Jana and Deb 2005; Carpousis 2007).  
mRNA stability is mainly influenced by sequences in the 5’ UTR which can 
provide protective 5’-terminal hair-pin structures or high-affinity ribosome binding sites, 
and to a lesser degree by sequences in the 3’ region (Bouvet and Belasco 1992; Emory et 
al. 1992; Arnold et al. 1998; Baker and Mackie 2003). Increasing the longevity of a 
messenger can thus be achieved by replacing the native 5’ UTR with 5’ UTR from 
messengers with known high stability, like the E. coli ompA transcript (Belasco et al. 
1986; Hansen et al. 1994). In addition, 3’ UTR hair-pin structures can stabilize mRNA by 
blocking exonucleotic degradation from the 3’ terminus (Newbury et al. 1987; Massé et 
al. 2003). The use of inserting stabilizing hairpin structures to both the 3’ and 5’ ends of 
transcripts have been reported (Smolke et al. 2000). 
A completely different approach is to use engineered strains with deficiencies in 
the RNase machinery. One such example is the Invitrogen BL21 star strain, which carries 
a mutation in the gene encoding RNase E (rne131 mutation) (Lopez et al. 1999). 
1.2.5. Engineering of the 5’ untranslated region for increased 
translation initiation efficiency 
 Regulation of translation is a very important level of gene expression control. The 
sequence and structure of the messenger RNA determine its interaction with the 
translational machinery and hence the efficiency and frequency of translation, and so both 
sequence and structure are possible targets for optimizing recombinant gene expression. 
The rate-limiting step for translation is generally considered to be the initiation of 
translation (Draper 1996; Skorski et al. 2006). The E. coli mRNA region important for 
initiation usually spans a few tens of nucleotides bracketing the translation start, thus 
including parts of the 5’ untranslated region (5’ UTR, also called “leader”) (Laursen et al. 
2005) and it is generally understood that the wide range of translation efficiencies 
observed for different mRNA molecules is predominantly due to unique structural 
features in this region (Makrides 1996). A highly translated mRNA contains some or all 
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of the following elements: (I) a Shine-Dalgarno (SD) sequence which interacts with the 
more-or-less complementary 3’ end sequence (…ACCUCCUUA-3’) of 16S rRNA (ASD) 
(Shine and Dalgarno 1974), (II) the translation initiation codon AUG (the frequency of E. 
coli start codons are AUG (83%), GUG (14%), or UUG (3%) (Ma et al. 2002)), (III) a 
pyrimidine tract that interacts with S1 ribosomal protein (Boni et al. 1991; Zhang and 
Deutscher 1992; Sengupta et al. 2001) and (IV) base-specific enhancer elements 
upstream (O'Connor et al. 1999) or downstream (Sprengart et al. 1996) of the initiation 
codon.  
 The importance of the SD sequence has been documented in studies where the 
expression of specific messengers is first reduced through mutations in the SD sequence 
and then restored through compensatory mutations in the ASD (Hui and de Boer 1987; 
Jacob et al. 1987). However, the strength of the SD sequence is only weakly correlated to 
translation levels (Lee et al. 1996), and the existence of natural messengers completely 
lacking SD sequences (Boni et al. 1991) and leaderless mRNAs (Moll et al. 2002) 
suggest that the other elements must be important as well.  
Another important determinant for translation initiation besides primary 
sequences is the structure of the mRNA molecule. The structure of the mRNA determines 
translation efficiency by inhibiting or permitting 30S ribosomal subunit access (de Smit 
and van Duin 1994; Ramesh et al. 1994), for instance can occlusion of the SD sequence 
and/or the initiation codon inhibit translation (Cruz-Vera et al. 2004).  
Several different strategies have been attempted to maximize translation initiation 
efficiency and to minimize mRNA secondary structure. A random alteration of the 
translation initiation region resulted in a library that when screened exposed mutants with 
a 10-fold difference in translational strengths (Simmons and Yansura 1996). The 
enrichment of adenine and thymidine nucleotides in the leader has been shown to 
enhance the expression of some genes (Chen et al. 1994). Mutations of positions 
upstream and downstream of the SD sequence have been shown to suppress formation of 
secondary structures and thereby enhance the translation efficiency (Coleman et al. 1985; 
Gross et al. 1990; Jiang et al. 2001). Translational enhancers have been utilized for 
improved recombinant expression. One example is the U-rich region upstream of the SD 
sequence in the E. coli atpE gene (McCarthy et al. 1985). This 30 base-pair sequence has 
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been used to successfully over-express the human interleukin-2 and interferon β genes 
(McCarthy et al. 1986). 
1.2.6. Optimizing codon usage 
 Each amino acid is encoded by more than one codon and each organism has its 
own bias in the usage of the 61 available codons. The intracellular tRNA populations are 
correlated to the codon bias of the mRNA population (Dong et al. 1996). Highly 
expressed genes tend to contain codons for which the cell has abundant tRNA whereas 
genes that are expressed at low levels tend to include rare codons. Such codon biases can 
be a  big problem for high-level expression of recombinant genes (Clark 1998). If the 
mRNA from the recombinant gene contains rare codons, or if the amino acid composition 
of the correlated protein is skewed compared to typical E. coli proteins (Table 3), it is 
possible that translational problems – including translational stalling, premature 
translation termination, translation frameshift and amino acid mis-incorporation – may 
occur, leading to reduction in quantity or quality of the protein synthesized (Goldman et 
al. 1995; Kane 1995; Kurland and Gallant 1996).  
General and unambiguous “rules” which predict whether the content of low-usage 
codons in a specific gene might adversely affect the efficiency of its expression in E. coli, 
have not been discovered (Zhang et al. 1991). The reason for this may be that several 
variables, such as positional effects, the clustering or interspersion of rare codons, mRNA 
secondary structure, and other effects, confound the experimental data, as shown for 
Plasmodium falciparum (Peixoto et al. 2004). 
The presence of the most infrequent E. coli codons, AGG and AGA for arginine, 
has been shown to be a limitation for expression of several mammalian genes in E. coli
(Kane et al. 1992; Hua et al. 1994). To circumvent this problem, the argU (dnaY) gene 
which codes for the tRNA for AGG and AGA has been co-expressed, and this resulted in 
high-level production of the target proteins (Chen and Inouye 1994; Hua et al. 1994). 
Such experiments validate the construction of strains that over-express tRNAs which will 
alleviate problems connected to infrequent codon usage in recombinant genes. An 
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example of such engineered strains is the Rosetta strain (Novagen) which carries tRNA 
genes for the rare codons AGG, AGA, AUA, CUA, CCC, and GGA. Derivatives of 
Rosetta have been constructed which harbors additional tRNA genes (Table 4). Another 
example is the BL21-CodonPlus-RP strain (Stratagene) which carries the argU gene. 
Additional versions of this strain have also been constructed which include more genes 
for rare tRNAs. 
Table 3: Rare codon usage in the Escherichia coli strains K12 and B. The codon frequencies are 
based on  codons from sequences submitted to the GenBank (Nakamura et al. 2000) 
Rare codons Amino acid Frequency (K12) Frequency (B) 
AGG Arg 0.11 0.21 
AGA Arg 0.20 0.24 
CGA Arg 0.35 0.24 
CUA Leu 0.39 0.34 
AUA Ile 0.43 0.50 
UGU Cys 0.51 0.42 
CCC Pro 0.54 0.24 
CGG Arg 0.54 0.50 
UGC Cys 0.64 0.58 
ACA Thr 0.70 0.61 
CCU Pro 0.70 0.58 
UCA Ser 0.71 0.61 
GGA Gly 0.79 0.82 
CCA Pro 0.84 0.74 
UCC Ser 0.86 0.80 
AGU Ser 0.87 0.90 
UCG Ser 0.89 1.14 
 Another approach to circumvent adverse codon bias is to chemically redesign the 
gene of interest, or parts thereof, thereby replacing all problematic codons with 
synonymous, frequently used codons (Gustafsson et al. 2004). Such de novo gene 
synthesis has traditionally largely been avoided due to high costs (Wu et al. 2004). 
Recently the synthesis of genes has gained more popularity as the technology has 
matured and the costs have dropped comparably to what has been observed for synthetic 
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oligonucleotides during the last two decades (Gustafsson et al. 2004). Such de novo gene 
synthesis services can also attempt to optimize the gene for increased mRNA stability by 
reducing stable structures, i.e. 5’ stem-loop formations, and, if desired, modulate the GC 
content according to the host.  
The results from codon-optimizing mammalian genes for expression in E. coli
frequently results in five to 15-fold increase in protein production, sometimes 
corresponding to about 5% of total soluble protein in the cell (Gustafsson et al. 2004), 
and has also been reported to reach between 10% and 20% in specific cases (Deng 1997; 
Feng et al. 2000). Still, de novo gene synthesis does not always lead to an increase in the 
expression of problematic heterologous genes, even when all the changes are 
synonymous, and in a few cases the reported expression levels decreased (Biemelt et al. 
2003; Warzecha et al. 2003). 
1.2.7. Optimizing recombinant protein quality 
Rapid production of recombinant proteins can lead to macromolecular crowding 
with unfavorable folding conditions, resulting in formation of structurally complex 
aggregates (inclusion bodies) (Betts and King 1999; Villaverde and Carrío 2003). 
Although inclusion body formation greatly simplifies protein purification, there is no 
guarantee that the necessary in vitro refolding will yield large amounts of correctly folded 
protein (Clark 2001). The yield after refolding is usually between 10 and 50% of the 
initial inclusion body volume (Carrío and Villaverde 2002). To prevent inclusion body 
formation when expressing recombinant proteins many approaches are possible: co-
expression of molecular chaperones, fusion with solubilization partners, lowering of 
temperature, use of weak promoters, addition of sucrose and glycyl betaine to the growth 
medium, translocation to the periplasm, fermentation at extreme pH values, and use of 
low copy number vectors (Makrides 1996; Schumann and Ferreira 2004; Terpe 2006).  
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1.2.7.1. Co-expression of molecular chaperones 
Cells have evolved an elaborate protein quality control system which includes the 
activity of molecular chaperones, proteins that bind the nascent polypeptide and prevent 
off-pathway aggregation reactions by transiently binding hydrophobic domains 
(Gottesman et al. 1997). Many different studies have documented the benefits on protein 
folding from co-expression of different chaperones (Amrein et al. 1995; Thomas and 
Baneyx 1996; Nishihara et al. 1998; Nishihara et al. 2000) Unfortunately, only the 
chaperone involved with the folding of the specific protein will have a beneficial effect 
on the protein’s folding, so identification and co-expression of the correct chaperone is 
essential (Baneyx 1999). 
1.2.7.2. Fusion partners for increased solubility and stability 
Expressing recombinant genes with protein fusion partners may enhance the 
solubility of the corresponding proteins, thereby preventing formation of inclusion bodies 
(Davis et al. 1999; Kapust and Waugh 1999; Sørensen et al. 2003). Fusion partners may 
also protect the recombinant protein from intracellular proteolysis (Martinez et al. 1995; 
Jacquet et al. 1999). Common fusion partners for increased solubility are E. coli maltose-
binding protein (MBP), glutathione-S-transferase and thioredoxin. Of these three, the 
maltose-binding protein has been demonstrated to be the most efficient (Kapust and 
Waugh 1999). Another good solubilization partner is E. coli N-utilizing substance A 
(NusA). Both MBP and NusA have been used for solubilization of highly insoluble 
single-chain antibodies in the cytoplasm of E. coli (Bach et al. 2001; Zheng et al. 2003).  
Fusion partners usually need to be removed after purification in vitro, and this is 
usually achieved by using cleavage sites between the fusion partner and the recombinant 
protein which facilitate site-specific proteolysis (Sørensen and Mortensen 2005).  
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1.2.7.3 Translocation to the periplasmic space or secretion to the extracellular 
growth media 
  
Another method to circumvent problems with inclusion body formation is to 
translocate the recombinant proteins to the oxidizing environment of the periplasm. In 
addition to minimizing inclusion body formation, the periplasm contains less proteases 
than the cytoplasm (Gottesman 1996), thereby increasing the biological activity, stability 
and solubility of translocated proteins. In addition, transport to periplasm can simplify 
downstream processes and secure N-terminal authenticity of the produced protein 
(Makrides 1996; Cornelis 2000).  
Another possibility is to secrete the recombinant protein into the extracellular 
growth medium. One advantage of secretion is that E. coli does not normally secrete 
proteins (Pugsley et al. 1997; Hannig and Makrides 1998) and thus contamination of the 
product by host proteins can be minimized. As for the periplasm, the proteolytic activity 
is much lower in the culture medium (Gottesman 1996). 
 Protein translocation and secretion in E. coli are complex processes and several 
factors can influence the success of translocating and secreting recombinant proteins 
(Mergulhão et al. 2005), including the size of the recombinant protein (Baneyx 1999; 
Palacios et al. 2001), the amino acid composition of the leader peptide as well as the 
target protein (Kajava et al. 2000; Belin et al. 2004), and the expression levels (Simmons 
and Yansura 1996). The last effect is probably a consequence of the limited secretion 
capacity of the E. coli transport machinery, and when overwhelmed the excess of 
expressed recombinant protein is likely to accumulate in cytoplasmic inclusion bodies 
(Mergulhão et al. 2004). 
E. coli does not naturally secrete  large amounts of proteins (Sandkvist and 
Bagdasarian 1996) but there are a few systems available for recombinant translocation 
with possibilities for subsequent secretion: The HlyA system is a type I system and as 
such transports protein in one step across the two cellular membranes, without a 
periplasmic intermediate (Binet et al. 1997). The SecB-dependent pathway, the signal 
recognition (SRP) and the twin-arginine translocation (TAT) pathways, are all type II 
systems which transport the protein to the periplasmic space (Mergulhão et al. 2005). The 
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Table 4: Examples of some E. coli strains available for recombinant protein production 
Strain Derivation Key features Reference or source 
BL21 B834 lon and ompT Novagen 
BL21 trxB BL21 trxB; lon and ompT. Novagen 
Bl21 
CodonPlus®-
RIPL 
BL21 Contains additional codons rarely used in E. coli; 
lon and ompT
Stratagene 
BL21 (DE3) BL21 Contains the T7 RNA polymerase necessary for 
T7 promoter activity. 
Novagen 
BL21 (DE3) 
pLysS 
BL21 Contains the T7 RNA polymerase necessary for 
T7 promoter activity; contains the T7 lysozyme 
which degrades T7 RNA polymerase. 
Novagen 
BLR BL21 recA; stabilizes tandem repeats; lon and ompT. Novagen 
HMS174 K-12 recA; rifampicin resistant. Novagen 
JM 83 K-12 Usable for translocating recombinant proteins into 
the periplasm. 
(High et al. 1993) 
Origami K-12 trxB and gor. Novagen 
Origami B BL21 trxB and gor; lon and ompT. Novagen 
Rosetta BL21 Contains additional codons rarely used in E. coli; 
lon and ompT.
Novagen 
Rosetta-gami BL21 trxB and gor; contains additional codons rarely 
used in E. coli; lon and ompT. 
Novagen 
BL21 star BL21 rne131; lon and ompT. Invitrogen 
MM-294 K-12 Contains mutations in the acetate formation 
pathway. 
(Bauer et al. 1990) 
One disadvantage of producing recombinant proteins in E. coli is its inability to 
form disulfide bonds in the cytoplasm. This inability is caused by the reducing 
environment of the cytoplasm as well as the activity of at least five proteins (thioredoxins 
1 and 2, and glutaredoxins 1,2 and 3 which are involved in the reduction of disulfide 
bridges that transiently arise in cytoplasmic enzymes (Åslund and Beckwith 1999). Key 
enzymes in disulfide bond formation regulation are thioredoxin reductase and 
glutaredoxin reductase (encoded by the genes trxB and gor, respectively), which reduces 
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oxidized thioredoxins and thereby recycles them (Prinz et al. 1997). As a consequence of 
this, hosts have been designed that are trxB and gor negative, resulting in increased 
cytoplasmic disulfide bond formation, e.g. the BL21 trxB, Origami, Origami B and 
Rosetta-gami strains. 
Another important host modification is adjusted tRNA pools for increased 
expression of genes with rare codons, as was discussed in Chapter 1.2.6. 
1.2.9. Optimizing growth conditions 
 Although the specific recombinant gene expression is reduced at high cell 
concentrations (Yoon et al. 2003) high cell density cultures (HCDC) of E. coli is 
commonly used for increased recombinant protein yield since the densities can reach in 
excess of 100 g/L (Lee 1996; Jeong and Lee 1999; Gerigk et al. 2002; Jeong et al. 2004). 
In addition, HCDC is a cost-effective methods, where the cost reduction is achieved due 
to reduction in size of fermentation equipment and upstream and downstream utilities 
(Shiloach and Fass 2005; Choi et al. 2006). 
 Care must be taken when optimizing HCDC since studies have shown that 
nutrient composition, nutrient feeding strategy and fermentation variables such as 
temperature, pH, acetate accumulation and dissolved oxygen can affect among others 
transcription, translation, proteolytic activities and secretion (Lee 1996). In addition, 
problems with heat and mass transfer are common. To solve these issues a variety of 
techniques have been developed, including the use of different nutrient feeding strategies, 
specific fermentation strains and the use of oxygen enriched air or pure oxygen (Lee 
1996). 
 Selection of nutrient feeding strategy is crucial because it affects the metabolic 
pathway fluxes and consequently affects the maximum attainable cell concentration, the 
specific productivity of recombinant protein expression and formation of by-products 
(Lee 1996). The simple feeding strategies such as rate feeding, increased feeding, or 
exponential feeding are commonly used (Qiu et al. 1998; Wong et al. 1998; Babu et al. 
2000). More advanced feeding strategies are those with feedback control (Shin et al. 1997; 
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Chao et al. 2002; Kleist et al. 2003; Hu et al. 2004; Yuan et al. 2004). These are based on 
the observation that pH and dissolved oxygen changes when the principal carbon source 
is depleted, and will use this as a cue for the addition of concentrated feeding solution to 
the bioreactor. Feedback systems prevent overfeeding of nutrients. 
 Different engineered strains of E. coli have been used in HCDC, mainly to 
alleviate problems arising from accumulated acetate which inhibits cell growth because 
of change in pH and anion-specific effects (Warnecke and Gill 2005). Some of these 
strains have defects in the acetate biosynthesis pathway, e.g. the MM-294 strains (Bauer 
et al. 1990; Farmer and Liao 1997). It has been shown that E. coli strain B has the 
advantage of producing much less acetic acid than K-12 strains even in the presence of 
excess glucose (Shiloach et al. 1996; Noronha et al. 2000). 
1.3. Recombinant protein production with the Pm promoter and its 
cognate transcription activator XylS 
1.3.1. The Pm promoter from the Pseudomonas putida TOL plasmid 
pWW0 
 The Pm promoter originates from the archetypal TOL plasmid pWW0 from P. 
putida (Williams and Murray 1974) which contains genes for toluene catabolism 
organized in two operons, the upper and meta pathway operons (Worsey et al. 1978; 
Ramos et al. 1997; Greated et al. 2002). The genes encoding the enzymes in the upper 
pathway, which oxidize toluene to benzoate and xylenes to toluates, are under 
transcriptional control of the Pu promoter (Harayama et al. 1989) whereas the second 
operon (the meta operon) contains the genes for the meta-cleavage pathway responsible 
for further oxidation and decarboxylation of the carboxylic acids to Krebs cycle 
substrates, and are under transcriptional control of the Pm promoter (Worsey and 
Williams 1975; Franklin et al. 1981; Harayama et al. 1984; Ramos et al. 1987).  
INTRODUCTION 
30 
 Transcription from Pu is controlled by the positive regulator XylR which is 
activated by substrates for the upper pathway (Abril et al. 1989; Delgado and Ramos 
1994), while transcription from Pm is controlled by the positive regulator XylS which is 
activated by substrates for the meta pathway, e.g. m-toluic acid (Inouye et al. 1981; 
Franklin et al. 1983; Ramos et al. 1986; Marqués et al. 1994). The basal expression from 
Ps2, one of xylS’ two promoters, establishes a basal, low expression level of XylS in the 
cells (Marqués et al. 1998). In addition, activated XylR stimulates transcription from Ps1, 
the second xylS promoter, leading to elevated levels of XylS and transcription stimulation 
from Pm. (Inouye et al. 1987; Marqués et al. 1998). 
1.3.1.1. Architecture of the Pm promoter 
 The Pm promoter extends to about 70 base pairs upstream of the transcription 
start site. It can be divided into two distinguishable regions: the XylS interaction region 
(the meta operator, Om), which extends from -34 to -69, and the downstream RNA 
polymerase recognition region  (Franklin et al. 1981; Harayama et al. 1984; Kessler et al. 
1993; Kessler et al. 1994; Gallegos et al. 1996; González-Pérez et al. 1999; González-
Pérez et al. 2002) (Figure 7).  
Om is composed of two 15-bp imperfect direct repeated motifs (5’-
TGCAAPuAAPyGGNTA-3’) extending from -69 to -55 and from -48 to -34. Mutation 
mapping has revealed that the nucleotides located at -48 to -45 and at -58, -59, -61, and -
69 are the most critical bases for appropriate XylS-Pm interactions (Kessler et al. 1993; 
Gallegos et al. 1996; González-Pérez et al. 1999). 
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in other organisms than Pseudomonas was examined, and it was shown that regulated 
expression from Pm was obtainable in many organisms, but not in Proteus mirabilis and 
Rhizobium meliloti. High expression levels were reached in many Pseudomonas
subspecies, Aeromonas hydrophila, Aerobacter aerogenes, Serratia marcescens, Erwinia 
carotovora and importantly, Escherichia coli (Mermod et al. 1986). In 1997 a new set of 
expression vectors based on Pm and XylS, the pJB vectors, was reported (Blatny et al. 
1997; Blatny et al. 1997). An expression cassette featuring Pm and xylS was combined 
with a minimal replicon based on the broad-host range RK2 plasmid. The minimal RK2 
replicon consisted of the origin of vegetative replication (oriV) and the trfA gene (Perri et 
al. 1991). By substituting the wild-type trfA gene with copy-up mutant genes the copy 
number of the pJB vectors can be increased 24-fold (Haugan et al. 1992) from its natural 
number of 5 to 7 per chromosome, although the maximum tolerance level of elevated 
copy numbers differs from species to species (Haugan et al. 1995). The strong correlation 
between inducer concentration and resulting transcription level from Pm has been used, 
together with Pm promoter mutants and trfA gene mutants, to obtain regulated 
recombinant protein expression levels from JB vectors covering a ten-thousand- to a 
hundred-thousand-fold continuous range, in several Gram-negative bacteria, and this 
expression has been shown to be useful for both metabolic engineering and maximized 
protein production (Blatny et al. 1997; Brautaset et al. 2000; Winther-Larsen et al. 2000; 
Gimmestad et al. 2003; Bakkevig et al. 2005). 
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2. AIMS OF THE STUDY 
The main goal of this study was to gain a deeper understanding of recombinant 
protein production in Escherichia coli with expression vectors based on Pm and xylS, the 
JB-vectors. As elaborated on in the preceding chapters there are many possible targets for 
maximizing recombinant protein production in E. coli. In this work it was decided to 
focus on some selected targets which were believed to yield insights into how the JB-
vectors can be applied for industrial scale production of proteins and illuminate 
fundamental mechanisms behind gene expression. These key targets were: 
• Studies on how the plasmid copy number of JB-vectors can be adjusted to 
maximize recombinant protein expression in high cell density cultures (HCDC). 
The human antibody fragment scFv-phOx was chosen as the model protein.  
• The use of different signal peptides for efficient translocation of recombinant 
proteins. It is known that different signal peptides can be used for translocation of 
recombinant proteins, but their relative efficiencies and their gene-specificities are 
largely unexplored. This research would in addition include the design of a novel 
signal peptide sequence based on a consensus sequence. The industrially relevant 
proteins scFv-phOx, hGM-CSF and hIFN-α2b were chosen for this study. 
• Directed evolution of the transcription activator XylS for increased induced 
stimulation of transcription from Pm. This would be the first time a bacterial 
transcription activator would be subjected to directed evolution for the purpose of 
increasing recombinant protein production.  
• Use results from the screening of the XylS mutant library to shed light on the 
structure/function relationship of XylS, and, if possible, use this information to in 
silico predict the XylS N-terminal domain structure. 
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• De novo synthesis of the IFN-α2b and xylS genes for circumventing low 
expression due to unfavorable codon usages.  
Investigations into these topics would hopefully result in a broader knowledge of 
this specific expression system which would greatly benefit its use in applied 
biotechnology and would be likely to have a general value applicable to other expression 
systems, both for use in E. coli and other bacterial hosts. 
In parallel with this project, other members of our research group have focused on 
other targets, including the DNA and RNA sequences affecting transcription and 
translation, respectively. 
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4. SUMMARY OF RESULTS & DISCUSSION 
4.1. High-level production of human proteins through use of signal 
peptides for translocation in high-cell density cultures 
(paper I and II) 
4.1.1 Selection of model proteins and construction of expression vectors 
for production of therapeutic proteins 
A derivative of the expression vector pJB658 (Blatny et al. 1997) was chosen for 
the production of the human antibody fragment scFv-phOx, transcribed from the Pm
promoter. scFv-phOx requires disulfide bond formation for correct folding, and therefore 
translocation to the E. coli periplasm is necessary. To facilitate efficient translocation, a 
cassette system was developed where sequences for different N-terminal signal peptides 
could easily be exchanged. To be able to quantify the production and purify the protein 
products, a c-myc and a his6 tag were included so as to be C-terminally fused to the 
expressed recombinant protein (Figure 9).
FIGURE 9: Map of the cloning and expression cassette vector featured on the pJB658 derivate used 
for expression of therapeutic proteins. The map shows restriction sites useful for gene cloning with 
and without a fused signal peptide sequence, as well as for exchanging the signal peptide sequence. 
The map starts with the Pm promoter and ends with the transcription terminator tLPP. pelB encodes 
an N-terminal signal peptide that directs translocation of scFv-phOx to the E. coli periplasm. 
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4.1.2. The highest production of scFv-phOx was reached with medium 
plasmid copy number 
The production yield of scFv-phOx from HCDC with varying copy number 
vectors was determined. As anticipated the scFv-phOx production increased when the 
wild type copy number (5-7 copies per chromosome) (vector pJBphOx) was elevated 
three-to-fourfold by use of the trfA mutant gene cop271C (vector pJBphOx-cop271), 
from about 0.8 g/L to 2.3 g/L with 3 mM m-toluic acid (Figure 10). Increasing the copy 
number further by use of the trfA mutant gene cop251 (vector pJBphOx-cop251), which 
raises the copy number eightfold, caused extensive plasmid loss before the time of 
induction, with resulting low scFv-phOx production.  
Figure 10: Total volumetric yields of scFv-phOx (soluble and insoluble) at different induction levels 
in HCDC fermentations with E. coli RV308 harboring pJBphOx and pJBphOx-271.  
By deleting a region of pJBphOx-cop251 encompassing essential parts of the xylS
gene the expression of scFv-phOx was greatly reduced, but the plasmid was then 100% 
stable. We therefore conclude that the reason for the observed plasmid loss is high basal 
expression from Pm caused by increased XylS levels resulting from elevated plasmid 
copy number, and not the high copy number per se. The increased basal expression of 
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scFv-phOx reduces the growth rate of the plasmid-containing cells and cells without 
plasmid thus take over the culture. Ampicillin in the broth will not counter this process 
since it is quickly degraded under HCDC conditions.  
The results indicate that it might have been possible to produce scFv-phOx from 
pJBphOx-cop251 if the basal expression from Pm could be kept low. This could perhaps 
be accomplished by controlling the expression of XylS from a tight promoter in trans. If 
so, it is possible that the production of scFv-phOx, or another protein of interest, may be 
increased. 
4.1.3. Signal peptides affect both translocation and expression of 
recombinant genes in a gene-specific fashion 
It is possible that signal peptides not only affect the translocation efficiency of the 
recombinant protein, but also the expression rates. To investigate this expression from the 
most productive vector, pJBphOx-cop271, but with pelB exchanged with two alternative 
signal peptides sequences, ompA and CSP, yielding the vectors pJBphOx-271ompA and 
pJBphOx-271CSP, were tested. The signal peptide sequence CSP was designed for this 
work and is based on the consensus sequence for signal peptides in gram negative 
bacteria. Both the productions of soluble and insoluble scFv-phOx from these new 
vectors were lower than with pelB (totaling 0.25 and 0.60 g/L with ompA and CSP, 
respectively) (Figure 11). Based on this it was concluded that the choice of signal peptide 
sequence has a strong impact on both the translocation and the expression level of 
recombinant scFv-phOx. 
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Figure 11: Production levels of scFv-phOx and GM-CSF with different signal peptide sequences, and 
no signal sequence, during HCDC. Both soluble and insoluble fractions are given for all recombinant 
strains tested. Production of synthetic IFN-α2b was not tested with ompA and CSP. Production of 
scFv-phOx without signal peptide in shake flask experiment gave no detectable product and was 
therefore not tested in HCDC. 
This was further confirmed by expressing GM-CSF with and without the PelB 
signal peptide (vector pGM29 with derivatives). Although GM-CSF does not need 
disulfide bond formation, and thus translocation to the periplasm, its expression was 
greatly enhanced when fused to PelB. The pelB sequence was then exchanged with ompA
and CSP and it was observed that the OmpA and CSP signal peptides cause an up to 
twofold higher production of GM-CSP than PelB (Table 5 and Figure 11), indicating that 
the effect of different signal peptides is highly gene-specific. 
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Table 5: Expression data of GM-CSF-producing strains during HCDC 
Protein product 
Plasmid Signal peptide 
Soluble Insoluble 
mRNA 
pGM29 None BD BD 1.0x ± 0.1x 
pGM29pelB PelB 0.39 ± 0.03 0.4 ± 0.05 3.0x ± 0.5x 
pGM29CSP CSP 0.80 ± 0.11 0.7 ± 0.15 3.4x ± 0.3x 
pGM29ompA OmpA 0.70 ± 0.09 1.0 ± 0.25 8.0x ± 0.9x 
BD: Below detection limit (below 1 mg/L). The values for soluble and insoluble protein yield are in g/L. 
To investigate whether the effect of signal peptides are at the level of 
transcription, translation, or both, quantitative PCR was used to measure GM-CSF 
mRNA levels (Table 5). These results show that the mRNA levels of strains with pelB
(pGM29pelB) and CSP (pGM29CSP) were only about three times higher than for the 
strain without signal peptide (pGM29), although the increases in total protein are much 
higher. This implies that the low GM-CSF expression level of pGM29 is largely due to 
inefficient translation and not poor transcription.  
The finding that signal peptides seem to have a general positive effect on 
expression of eukaryotic recombinant genes might have big implications for recombinant 
protein production in bacteria. The low translation of recombinant genes that are 
evolutionary distant from the host cell is possibly caused by sequences in the start of the 
coding region that lower the translation initiation efficiency, perhaps by forming 
secondary structures that shield the translation machinery from the translation initiation 
region of the mRNA (Simmons and Yansura 1996; Puri et al. 1999). This phenomenon 
will be further studied in Chapter 4.4. By separating the recombinant gene from the 5’ 
UTR with a signal peptide sequence known to be efficiently translated such inhibitory 
secondary structures are less likely to form. If so, substituting signal peptide sequences 
with other well-expressed sequences should also overcome this problem. 
The observation that the effect of signal peptides is gene-specific represents an 
obstacle to optimal utilization of signal peptides for recombinant protein production. The 
reason for this gene-specificity might be interaction(s) between the signal peptide 
sequence and the start of the recombinant gene at the transcriptional and/or translational 
level, causing bottlenecks in expression. In that case, no single signal peptide may be 
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found that can lead to high level expression of any recombinant gene, but if the 
interactions can be understood it might be possible to engineer signal peptides for each 
recombinant gene of interest, resulting in maximized expression. Another point is that 
maximized expression may not be compatible with maximized translocation efficiency, 
and thus compromises between the two may be necessary. 
4.1.4. The expression level of human IFN-α2b is low partly because of 
unfavorable codon usage 
Production of IFN-α2b was below the detection limit both with and without signal 
peptides. Detection of product from E. coli strain BL21-CodonPlus(DE3)-RIPL indicated 
that this was caused by unfavorable codon usage. To obtain good production of this 
protein the IFN-2αb gene was de novo synthesized to contain optimal E. coli codon 
usage. The newly synthesized IFN-α2b gene was then expressed fused to the pelB signal 
peptide sequence and a yield of about 0.6 g/L was obtained (Figure 11). All of the 
produced protein was found as insoluble aggregates.
The starting point for de novo synthesizing of the IFN-α2b was no detectable 
production. This must not be understood to imply that low initial production is a 
prerequisite for using synthetic recombinant genes; it may still be possible to obtain an 
increase in production from synthesized genes that initially have a detectable production, 
although the rationale for such an approach may be correspondingly weaker.  As the costs 
of gene synthesis continue to drop, synthesis of genes may become popular even for 
genes that are already expressed relatively efficient, even if the obtained production 
increase is modest because of limitations posed by other bottlenecks in expression. 
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communication between the N- and C-terminal domain, RNA polymerase contact and 
thermodynamic stability.  
The structure compose of the first 39 residues of XylS were not predictable. In 
AraC the first 15 residues constitute an arm which in the uninduced state represses the 
DNA-binding efficiency of the regulator and closes the β-barrel in the induced state, 
thereby freeing the DNA-binding domain (Ghosh and Schleif 2001; Wu and Schleif 
2001). If this “light-switch mechanism” was true for XylS as well, then deletion of the 
first 39 residues of the N-terminal region should give a constitutive phenotype, but such a 
XylS deletion mutant protein has been shown to be almost completely inactive (Kaldalu 
et al. 2000).  
The aggregation of XylS and other AraC/XylS family members when 
overproduced is well-known (Lorenzo et al. 1993; Michán et al. 1995; Bhende and Egan 
2000; Timmes et al. 2004). It is tempting to suggest that this phenomenon prevents 
adverse effects from supernormal concentrations of these transcription activators, such as 
stimulation of non-cognate promoters. Recently it has been shown that tyrosine 31 of 
AraC is at least partly responsible for aggregation when the protein is over-expressed 
(Weldon et al. 2007). Sequence alignment of AraC and XylS indicates that tyrosine 31 
from AraC might be conserved in position 61 in XylS, suggesting that an identical 
mechanism may be at work for XylS. 
The XylS NTD is connected to the XylS CTD through a flexible linker in the 
region of residues 200 to 211, which has not been possible to model. No substitutions 
affecting XylS function has been found in this region so the role of the linker is probably 
restricted to supplying a connection between the two domains, as shown for RhaS and 
RhaH (Kolin et al. 2007), and possibly provide the flexibility necessary for normal 
function of the activator, as shown for AraC (Eustance and Schleif 1996). 
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4.2.3. Combinations of mutations cause apparently unpredictable 
induction properties of the resulting mutant XylS activators 
To test whether different XylS substitutions can be combined to yield XylS 
activators that further increase transcription from Pm, activators containing two or three 
substitutions were designed rationally via site-specific mutagenesis of xylS. Both 
substitutions identified after error-prone PCR and the R45T substitution which has 
previously been shown to increase XylS activity (Ramos et al. 1990), were combined. 
Eighteen different combinations were tested, and all of them gave their hosts higher 
induced ampicillin tolerance than the cells with XylS proteins with only single 
substitutions (Figure 15), verifying that the XylS substitutions can work in an additive 
manner. The XylS protein Syn-15 (containing the three substitutions F3Y, I50T and F97L) 
gave 5.9 to 6.2 times higher induced ampicillin tolerance than wild type, and only 1.4 to 
1.7 fold higher basal ampicillin tolerance, thus increasing the induction ratio from 17 for 
wild type XylS to at least 56 with Syn-15. 
It was not possible to predict the tolerance levels of cells with different xylS
mutations because no specific correlation between combinations of xylS mutations and 
tolerance levels of the cells were discernable, although there was a general trend that 
combination of many mutations increased the tolerance. This observation suggests that 
optimal combinations of xylS mutations can be identified only from screening a randomly 
shuffled xylS mutant library.  
4.2.4. DNA shuffling of mutant xylS genes and selection of XylS mutants 
proteins with further improved activation properties 
To circumvent the unpredictable ampicillin tolerance levels observed upon the 
rational combinations of useful xylS mutations, a staggered extension process (StEP) 
DNA shuffling strategy for random recombination of mutant xylS genes was employed. A 
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4.3. Selection for constitutive XylS mutant proteins resulted in 
isolation of xylS mutant genes containing a novel promoter that 
increase expression from Pm independent of XylS  
(unpublished results) 
4.3.1. Selection for constitutive activity from the Pm promoter resulted 
in the isolation of a xylS mutant gene with the silent mutation G33A and 
the stop codon mutation C454T  
It was decided to screen the XylS mutant library for mutants with enhanced ability 
to stimulate transcription from Pm in the absence of inducers (constitutive XylS mutant 
proteins). Such proteins can be useful for recombinant expression when controlled 
expression is unnecessary and they may help to elucidate the mechanisms behind XylS’ 
stimulation of transcription from Pm. 
The screening resulted in identification of 14 mutated xylS genes conferring a 25 
to 250-fold increase in basal expression from Pm. The induced expression was also 
increased, although not to the same degree, and thus the isolated XylS mutant proteins 
were still regulatable (results not shown), at least to some extent.  
Sequencing showed that 10 of the xylS mutant genes contained the silent point 
mutation G33A in addition to other mutations which varied among the mutant genes. 
Surprisingly, one of the xylS mutant genes contained the point mutation C454T in 
addition to G33A. C454T results in a stop codon (UGA) which should truncate the gene 
product at residue 152. The resulting truncated XylS mutant protein would lack the entire 
C-terminal domain assumed to be essential for DNA-binding and hence transcription 
stimulation.  
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4.3.2. A truncated version of xylS when combined with the silent G33A 
mutation is able to increase transcription from Pm  
To verify that the observed high basal ampicillin tolerance level resulted from the 
xylS mutation G33A, site-specific mutagenesis was used to introduce this mutation in a 
xylS gene (xylS-G33A) and it was observed that the host cell’s basal ampicillin tolerance 
increased from 25 (with wild type xylS) to about 450 μg/mL. Quantitative real-time PCR 
verified that this increase in basal ampicillin tolerance was in fact a result of increased 
transcription of bla. 
Addition of the C454T mutation (generating the UGA stop codon) did not change 
the basal tolerance level, but a xylS gene with only the C454T mutation gave a tolerance 
resistance level of 25 μg/mL, indicating that the UGA is read as a stop signal. A xylS
gene with the point mutations C454T, G455A and A456G, generating the strongest stop 
codon UAG, was then constructed. Again, in combination with the G33A point mutation 
the cells were able to grow to high ampicillin concentrations in the absence of m-toluic 
acid, indicating that the G33A point mutation is not somehow stimulating translational 
read-through of the UGA stop codon. Then xylS genes, with or without the G33A point 
mutation, with the 3’ end starting from nucleotide 455 removed, were generated (xylS-
∆455 and xylS-G33A,∆455, respectively). The corresponding cells behaved as their stop 
codon counterparts confirming that the stop codons are read as translation termination 
signals (Figure 16). 
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Figure 16: Different xylS mutant genes and their host cell’s upper ampicillin tolerance limit (given in 
μg/mL) in the presence (+) of 1 mM m-toluic acid and its absence (-). The G33A mutation is silent 
(Q11Q); C454T generates an UGA stop codon and the C454T, G455A, A456G generate an UAG stop 
codon. The stop codons correspond to position 152 at the protein level.  
4.3.3. xylS-G33A is dependent upon in cis configuration to increase 
expression from Pm
To investigate whether the xylS-G33A was dependent upon an in cis configuration 
to increase expression of bla, a set of vectors based on a pET16 replicon with regions 
from the pTA13 vectors were generated. The regions contained the xylS promoters Ps1
and Ps2 and the entire xylS gene coding region. To be able to select for these plasmids, 
and to avoid interference with the ampicillin selection system, the vectors contained the 
tetracycline resistance marker. The wild type xylS gene featured on pTA13 was deleted 
resulting in the vector pTA13∆xylS. Each pET16-tc derivate could now be used together 
with pTA13∆xylS to investigate the individual xylS mutant genes’ ability to stimulate 
transcription from Pm when positioned in trans (Table 6). 
The results showed that xylS-G33A leads to a two-fold decrease in induced 
ampicillin tolerance when in trans compared to wild type xylS. The truncated xylS gene 
with G33A (xylS-G33A,∆455) was also not able to stimulate expression of bla, and 
behaved like a truncated xylS gene without G33A. For the truncated xylS genes an inducer 
effect of about two to three (from 60-65 to 100-200 μg/mL) was observed, but this is 
SUMMARY OF RESULTS & DISCUSSION 
56 
explained by m-toluic acid stimulating the heat shock response and thus leading to more 
transcription from Pm through elevated levels of σ38 (Marqués et al. 1999). It was 
concluded that xylS-G33A is not able to increase transcription from Pm when in trans, 
with or without truncation. 
Table 6: Upper ampicillin tolerance levels of cells with xylS mutant genes in trans  
Vectors + (μg/mL) - (μg/mL) 
pTA13∆xylS     100-200 60-70 
pTA13∆xylS; pET16-tc:Ps1Ps2-xylS 1600-1650 60-65 
pTA13∆xylS; pET16-tc:Ps1Ps2-xylS-G33A     800-900 60-65 
pTA13∆xylS; pET16-tc:Ps1Ps2-xylS∆455     100-200 60-65 
pTA13∆xylS; pET16-tc:Ps1Ps2-xylS-G33A,∆455     100-200 60-65 
(+ denotes the upper ampicillin tolerance limit in the presence of 1 mM m-toluic acid and - in its absence) 
4.3.4. The G33A point mutation apparently generates a new promoter 
causing Pm-independent transcription of the bla gene 
As a result of the finding that xylS-G33A only increases the basal expression from 
Pm when in cis, the genetic context of the mutation was scrutinized and it was discovered 
that it generates a possible new -35 region reverse positioned relative to transcription of 
xylS, in the 5’ end of the xylS coding region (Figure 17). If so, the putative transcript 
traverses the more than 800 base pair span between the start of the xylS coding region and 
the bla gene resulting in increased levels of bla transcript available for translation. To test 
this hypothesis the Pm promoter in a pTA13 derivate was exchanged with the 5’ region of 
xylS either containing the wild type sequence or the sequence with the G33A point 
mutation. The ampicillin tolerance levels of the cells were significantly increased with the 
putative promoter compared to the wild type region (results not shown), proving that 
G33A creates a new promoter. This also proves that the observed increase in bla
transcript with the G33A point mutation is not caused by a change in XylS function or 
concentration, but an increase in bla transcript originating from a new promoter more 
than 800 base pairs distant from the bla gene. 
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Figure 17: Sketch of the area encompassed by the xylS gene coding region and the bla gene coding 
region. The putative -10 and -35 regions of the new promoter are shown within the xylS gene. The 
G33A point mutation, relative to the xylS gene, is shown in bold and underscored. mRNAs generated 
from the Pm promoter and the new promoter, are indicated. The figure is not drawn to scale, and the 
distance between the start of the xylS gene and the start of the bla gene is approximately 800 base 
pairs. 
These results suggest that to successfully isolate constitutive XylS mutant proteins 
the pTA13 vector is not optimal. The addition of a transcription terminator between the 
xylS and the bla gene would exclude any point mutations like G33A and thus increase the 
possibility of selecting constitutive XylS mutant proteins. 
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4.4. De novo synthesized xylS is not properly translated 
(paper IV) 
4.4.1. The expression level of wild type XylS in E. coli may be limited by 
unfavorable codon usage 
In an attempt to over-express XylS for structure determination, the vector pET16b 
was used to drive xylS expression from the strong T7 promoter. By testing out different E. 
coli expression strains it was observed that XylS could only be detected from the BL21-
CodonPlus® (DE3)-RIPL strain which contains additional copies of tRNA genes (results 
not shown). Based on this result the codon frequencies of xylS were analyzed and 
compared to E. coli strain K12 and B (Table 7). The analysis showed that xylS contains 
the arginine codons AGG, CGA, CGG, the leucine codon CTA, the isoleucine codon 
ATA, the proline codon CCC, and the cysteine codon TGC in frequencies at least 2.5 
times higher than in E. coli strain B and K12. It therefore seemed possible that the 
specific codon usage in the xylS gene is a bottleneck for its efficient expression in E. coli.  
Table 7: Rare codons in E. coli strain B and K12 (Nakamura et al. 2000) with frequencies and 
occurrences in the xylS gene 
Rare codons in E. 
coli K12 and B 
Encoded 
amino acid 
Frequency per 1000 
codons (K12/B) 
Frequency in xylS per 
1000 codons 
Occurrence in 
xylS
AGG Arg 1.1/2.1 12.8 4 
AGA Arg 2.0/2.4 3.1 1 
CGA Arg 3.5/2.4 9.4 3 
CTA Leu 3.9/3.4 9.4 3 
ATA Ile 4.3/5.0 12.8 4 
TGT Cys 5.1/4.2 9.4 3 
CCC Pro 5.4/2.4 12.8 4 
CGG Arg 5.4/5.0 12.8 4 
TGC Cys 6.4/5.8 21.8 7 
ACA Thr 7.0/6.1 3.1 1 
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4.4.2. The translation efficiency of a de novo synthesized and codon-
optimized xylS gene is severely reduced compared to the wild type gene 
To overcome reduced expression of the xylS gene caused by its frequent use of 
rare codons, a synthetic version of xylS, syn-xylS, was synthesized de novo. The syn-xylS
gene was designed to have a codon usage as similar to E. coli as possible, and the codons 
AGG, CGA, CTA, ATA, CCC and CGG were removed altogether from the gene. All of 
the changes in syn-xylS were synonymous, securing that the gene product from xylS and 
syn-xylS are identical. The xylS gene in the vector pTA13 (Figure 12) was exchanged 
with the syn-xylS gene, creating the vector pTA13:syn-xylS. Induced E. coli cells 
harboring pTA13:syn-xylS could not grow on media containing more than 100 μg/ml 
ampicillin, indicating a reduction in stimulation of transcription from Pm.  
Real time PCR experiments with primers directed against syn-xylS showed that 
the amount of syn-xylS mRNA were similar to the amount of wild type xylS mRNA from 
pTA13 (data not shown). Based on this it was concluded that the synthetic xylS gene, 
although it has been codon optimized, has acquired some elements that strongly reduce 
the translational efficiency of its mRNA. 
4.4.3. Mutations in the 5’ 44 base pairs of synthetic xylS reduce efficient 
translation of its messenger 
To locate the region within the syn-xylS responsible for the reduced translation, a 
PshAI restriction site in xylS (Figure 12) was used to construct two xylS chimera genes, 
one based on wild type xylS with the 5’ 164 base pairs from syn-xylS, designated syn[1-
164]; and one based on syn-xylS with the 5’ 164 base pairs from wild type xylS, 
designated syn[165-966]. The ampicillin tolerance of cells containing the plasmid 
pTA13-syn[1-164] was measured to be between 0.13 and 0.15 of the tolerance of cells 
harboring wild type xylS, while cells containing the plasmid pTA13-syn[165-966]
displayed wild type ampicillin tolerance (580 μg/mL).  
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Gene sowing was then used to exchange parts of the 5’ 164 base pairs of wild 
type xylS with the corresponding sequences from syn-xylS. All the cells containing novel 
chimeric xylS genes had an ampicillin tolerance level of 0.13 to 0.15, compared to cells 
harboring wild type xylS, including cells containing the chimera with the shortest 
sequence from syn-xylS, syn[1-44], containing only eight mutations. The mutations in 
syn[1-44] are shown in Figure 18. From these results it was concluded that the region 
responsible for the reduced translation is located within the first 44 base pairs of syn-xylS. 
Figure 18: Schematic overview of the 5’ 42 base pairs end of the xylS coding region in different xylS
mutant genes. The sequence of wild type xylS is shown on top. For the different xylS mutant genes 
only the mutations are indicated. The base pair positions of the eight different mutations are shown 
above the xylS sequence. The induced (1 mM m-toluic acid) ampicillin tolerance levels for cells 
harboring these xylS gene derivatives on the pTA13 plasmid are shown relative to the resistance level 
of cells with wild type xylS, set to 1.00.  
Under the assumption that the reduction in syn-xylS translation might be caused 
by a single mutation within the first 44 nucleotides of the syn-xylS gene, each of the first 
eight mutations in syn-xylS were reversed by site-specific mutagenesis, and the ampicillin 
tolerance levels of cells containing the corresponding pTA13 derivatives were measured. 
None of the cells had gained ampicillin tolerance levels similar to cells containing wild 
type xylS (data not shown). 
A set of new xylS genes was designed with site-specific mutagenesis with 
increasing numbers of mutations from syn-xylS (Figure 18), were then constructed. The 
results showed that the full reduction in ampicillin tolerance was only reached for the 
xylS gene containing all the eight mutations from the 5’ 44 base pairs of syn-xylS.   
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4.4.4. Most of the mutations in the 5’ 44 base pairs of synthetic xylS
apparently reduce its translation, but the full reduction can be achieved 
by a single mutation at position 42 
Since many of the mutations in syn[1-44] affect expression of the xylS gene, it 
was decided to investigate the individual effect of each mutation by constructing, with 
site-specific mutagenesis, eight xylS genes each featuring one of the eight mutations 
found within syn[1-44]. The results of the corresponding phenotype analyses showed that 
every mutation except the 5th (syn27) diminished the ampicillin tolerance. In addition, the 
8th mutation (syn42) alone caused the full reduction in ampicillin tolerance observed for 
syn-xylS (Figure 19). From this it was concluded that many positions at the 5’ end of the 
xylS gene are necessary for normal translation efficiency of the xylS mRNA, and that one 
specific mutation (at position 42) has a particularly strong negative effect. 
Figure 19: Schematic view of the 5’ 42 base pairs end of different xylS mutant genes. See legend of 
Figure 18 for further details. 
 The finding that a synthetic version of xylS is apparently not properly translated 
was surprising, especially considering that it was designed for optimal translation. Since 
the region responsible for the reduced translation is at the beginning of the coding 
sequence, it is tempting to hypothesize that the cause is reduced translation initiation, and 
not elongation or termination, presumably caused by inhibitory mRNA secondary 
structures. If so, the algorithms for optimizing mRNA secondary structure, as 
implemented in the design of the synthetic gene, are far from optimal.  
The observation that apparently neutral base substitutions can have drastic effects 
on gene expression is obviously of significant interest for the entire technology of using 
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synthetic genes to improve gene expression. The observation may also have relevance for 
the understanding of expression of natural genes, and an understanding of the underlying 
mechanisms may therefore be of broad interest. 
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5. CONCLUSIONS 
The work presented in this thesis has focused on broadening our knowledge of 
recombinant expression in E. coli with emphasis on high-level protein production. Key 
topics have included the use of signal peptides for increased recombinant expression and 
efficient translocation of the gene product, directed evolution of a transcription regulator 
for tightly regulated and increased induced expression, and the use of synthetic genes to 
overcome unfavorable codon usage. 
During studies of recombinant expression of human proteins, it was discovered 
that signal peptides, which are thought to chiefly enable translocation over the inner 
membrane, have a profound positive effect on the recombinant gene’s overall expression. 
Unfortunately, there was clear gene-specificity regarding which signal peptide would 
yield the strongest effect on expression effect. To try to overcome this problem with 
natural occurring signal peptides, a synthetic signal peptide (CSP) based on signal peptide 
consensus sequence was rationally designed, but again the gene-specificity was observed. 
Hence, no tested signal peptide was optimal for any given recombinant gene. Therefore, 
it was concluded that signal peptides have the potential to improve expression of 
recombinant genes, but that some effort must be undertaken to identify the optimal signal 
peptide for the specific recombinant gene of interest. Further work must be done to 
elucidate this phenomenon and hopefully gain an understanding broad enough so that 
specific signal peptides can be designed for each and every recombinant gene to be 
expressed. 
The importance of tight recombinant protein expression was clearly observed in 
the study of scFv-phOx with elevated vector copy numbers. At high copy numbers the 
leakage, apparently caused by excessive amounts of XylS, resulted in extensive plasmid 
loss and subsequent drop in production. Work is at hand to obtain Pm promoter mutants 
with reduced leakage.   
Improving transcription regulators through directed evolution is a new approach 
for optimizing expression systems with respect to maximized recombinant expression. In 
this work it has been shown that this is a feasible method at least for XylS and that the 
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gain can be a 10-fold increase in induced expression of both bacterial (e.g. bla) as well as 
eukaryotic genes (i.e. scFv-phOx), without a proportional increase in the basal expression. 
It is reasonable to assume that this approach can be used with success on other 
transcription activators since these are presumably not evolved for maximum 
transcription stimulation. Many transcription factors used in expression systems are 
repressors, and their usefulness as templates for directed evolution in effort to obtain 
higher recombinant expression, is limited.  
During this work the N-terminal structure of XylS was in silico predicted and a 
3D structural model was built. The 3D model suggested that the individual mutations 
found to cause elevated expression from Pm were localized in varying sub-domains of the 
XylS structure, indicating that methods focusing on mutating smaller parts of a regulator 
may not be optimal. Many underlying mechanisms are responsible for the overall 
function of a transcription regulator and all of these might potentially be targets for 
improvement. 
There is no reason to assume that the 10-fold improvement that was obtained 
represents a maximum, it is probably possible to increase XylS’ ability to stimulate 
transcription from Pm even further through additional evolutionary steps, including the 
introduction of new mutations in a second round of error-prone PCR. Still, the presented 
results indicate that mutations that improve the induced expression also increase the 
system’s basal expression, although at a lesser degree. Hence, if low basal expression is 
considered essential further evolution might be counter-productive. In addition to proving 
that directed evolution is a feasible approach for improving XylS for recombinant 
expression, it seems reasonable to believe that this general approach is applicable also to 
other transcriptional activators, both prokaryotic and eukaryotic. 
In an attempt to overcome unfavorable codon usage in the xylS gene and the gene 
for IFN-2αb, synthetic versions were designed for optimized translation in E. coli. For 
IFN-2αb this resulted in high-level production. For xylS, on the other hand, the synthetic 
gene was, surprisingly, not properly translated. The reason for this reduced translation 
was found to be changes in the 5’ coding region. One of these changes, in position 42, 
was sufficient to reduce its translation (presumably), as measured by a reduction in bla
expression from Pm, down to about 10% (relative to wild type xylS), although many other 
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changes in the 5’ region also reduced bla expression. Future work will focus on revealing 
the mechanisms behind this reduction as well as quantifying the reduction of XylS 
proteins from syn-xylS relative to wild type xylS.  
Through this work the current knowledge of recombinant protein expression has 
been expanded. The results both broaden the understanding of this fundamental process 
as well as shed light on methods useful for improving recombinant expression at 
industrial scales. 
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In industrial scale recombinant protein production it is often of interest to be able to translocate the product
to reduce downstream costs, and heterologous proteins may require the oxidative environment outside of the
cytoplasm for correct folding. High-level expression combined with translocation to the periplasm is often toxic
to the host, and expression systems that can be used to ﬁne-tune the production levels are therefore important.
We previously constructed vector pJB658, which harbors the broad-host-range RK2 minireplicon and the
inducible Pm/xylS promoter system, and we here explore the potential of this unique system to manipulate the
expression and translocation of a host-toxic single-chain antibody variable fragment with afﬁnity for hapten
2-phenyloxazol-5-one (phOx) (scFv-phOx). Fine-tuning of scFv-phOx levels was achieved by varying the
concentrations of inducers and the vector copy number and also different signal sequences. Our data show that
periplasmic accumulation of scFv-phOx leads to cell lysis, and we demonstrate the importance of controlled
and high expression rates to achieve high product yields. By optimizing such parameters we show that soluble
scFv-phOx could be produced to a high volumetric yield (1.2 g/liter) in high-cell-density cultures of Escherichia
coli.
The application range of antibodies in medicine and bio-
technology is broad, and there has been great progress in the
design and selection of new variants with novel afﬁnities. In
particular, there has been a growing interest in the develop-
ment of antibody fragments comprising the VH and VL do-
mains connected to each other as a single chain (scFv) (4). The
small size of scFv proteins (about 250 amino acids) compared
to native antibodies confers certain therapeutic advantages
because of their shorter half-life (rapid blood clearance) and
faster tissue penetration. scFv molecules can be used as selec-
tive carriers for delivering radionucleids, toxins, or cytotoxic
drugs to malignant cell populations, as well as providing valu-
able tools for studying antibody-antigen interactions in detail
(14). In addition, this feature makes it possible to construct and
screen large scFv libraries by using phage display approaches
(for a review, see reference 23).
For medical applications scFvs are needed in large
amounts, and the ability to produce high yields in Esche-
richia coli has gained considerable interest (14). Native scFv
proteins have two disulﬁde bonds and require oxidative condi-
tions to fold correctly. Although expression of native scFv pro-
teins without disulﬁde bridge formation has been reported (9),
cytoplasmic production in bacteria typically results in aggregation
of scFv polypeptides into insoluble inclusion bodies (14).
Therefore, in E. coli it is usually desirable to express scFvs as
fusion proteins targeted for translocation to the oxidative peri-
plasm to obtain functional products (3, 26). Various vector
systems for recombinant scFv expression in E. coli have been
reported (11, 15, 19), but the experiments were typically per-
formed in shake-ﬂask cultures with product yields of 10 to 30
mg/liter. Plasmid-based gene expression under high-cell-density
cultivation may dramatically promote problems related to plas-
mid instability and lysis of recombinant cells (16, 28). There-
fore, to obtain industrially relevant yields of soluble scFv, the
expression tools should preferentially allow tight control of the
expression level and the plasmids must be kept stable under
high-cell-density cultivation.
We previously developed broad-host-range expression vec-
tors based on the minimal replication elements oriV and trfA of
the natural RK2 plasmid (5, 6). The trfA gene encodes a repli-
cation initiation protein also exerting negative control on rep-
lication from oriV (10, 12), and inducible expression of recom-
binant genes is governed by the ﬂexible Pm/xylS promoter/
regulator system. Relevant characteristics of these vectors
include adjustable vector copy number, the Pm promoter is
very strong and active in many hosts, several cheap and harm-
less (like benzoic acid) inducers can be used and they act in a
dose-dependent manner, and inducer uptake is based on pas-
sive diffusion which further simpliﬁes the use of the system
across species barriers. With one such vector, pJB658, we have
demonstrated regulated high and low level recombinant gene
expression in several gram-negative bacterial species (6, 7, 29).
In the present study we utilize the unique properties of pJB658
to express a host-toxic antibody fragment, scFv-phOx, in high-cell-
density cultivation of E. coli. By optimizing the vector copy num-
ber, induction conditions and choice of signal sequence, we pro-
duce recombinant scFv-phOx to very high volumetric yield (2.3 g/
liter) of which 60% is represented as soluble and active product.
* Corresponding author. Mailing address: Department of Biotech-
nology, Norwegian University of Science and Technology, N-7034
Trondheim, Norway. Phone: 47 73 59 86 89. Fax: 47 73 59 12 83.
E-mail: Trygve.Brautaset@nt.ntnu.no.
7033
MATERIALS AND METHODS
Strains, plasmids, and DNA manipulations. The strains and plasmids used in
this study are listed in Table 1. Standard DNA manipulations were performed as
described elsewhere (25).
Construction of vector pJBphOx. The scFv–2-phenyloxazol-5-one (phOx) cod-
ing sequence fused to c-myc was PCR ampliﬁed from vector pHOG21-phOx with
the following primer pair: scFv-F1, 5-TTACTCGCGGCCCAGCCGGCCATG
GCGCAGGTGCAGCTGGTGCAGTCT-3, and scFv-R1, 5-GTGATCGGCC
CCCGAGGCCTTTAGGTCTTCTTCTGAGATCAGCTTTTGTTC-3.
The PCR was performed on the Perkin Elmer GeneAmp PCR system 2400.
The resulting 843-bp PCR product was end digested with SﬁI (recognition sites
are italic in the primer sequences) and cloned between the two SﬁI sites of
plasmid pHKK. From this construct, the 2,420-bp NdeI/EcoRI fragment was
excised and cloned into the corresponding sites of plasmid pJB658, yielding
vector pJBphOx (Fig. 1).
Construction of the ompA and consensus signal peptide signal sequences. The
DNA molecules encoding OmpA and consensus signal peptide were made syn-
thetically by annealing of the following single-stranded oligonucleotide pairs:
ompA-F, 5-TATGAAAAAAACTGCTATCGCTATCGCTGTTGCTCTGGCT
GGTTTCGCTACTGTTGCTCAGGCGGCGGC-3, and ompA-R, 5-CATGG
CCGCCGCCTGAGCAACAGTAGCGAAACCAGCCAGAGCAACAGCGA
TAGCGATAGCAGTTTTTTTCA-3, and CSP-F, 5-TATGAAAAAAAAATT
ATTGGCGTTAGCCTTGTTAGCGTTATTGTTTAACGGCGCGCAGGC-
3, and CSP-R, 5-CATGGCCTGCGCGCCGTTAAACAATAACGCTAACAA
GGCTAACGCCAATAATTTTTTTTTCA-3.
Each pair of oligonucleotides were annealed as described previously (30) and
the NdeI (2 bp) and NcoI (4 bp) sticky ends formed at the ends of the resulting
double-stranded DNA fragments are in italic. The double-stranded DNA mol-
ecules obtained could be directly cloned into the NdeI/NcoI sites of any plasmid.
Media, feeding solutions, and preparation of inoculum to high-cell-density
cultivation fermentations. For routine cloning experiments and estimation of
plasmid copy number, E. coli cells were grown at 37°C in liquid Luria broth (LB)
or on solid Luria agar (LA) plates (25). The deﬁned preculture medium and the
main culture medium used were composed as described by others (13), whereas
feeding solution 1 was slightly modiﬁed and contained glucose (480 g/kg solu-
tion) and MgSO4  7H2O (15.8 g/kg solution). All media, unless otherwise stated
in the text, were supplemented with ampicillin (0.1 g/liter), and tetracycline (12
mg/liter) was used when appropriate.
The fermentation inoculum was prepared as follows. E. coli was grown over-
night at 30°C on LA plates, and single colonies were transferred to 100 ml of LB
medium in shake ﬂasks (500 ml bafﬂed) and incubated for 7 h at 30°C (200 rpm;
orbital movement amplitude, 2.5 cm). Cells were diluted 200-fold into 100 ml of
prewarmed preculture medium, and growth was continued at 30°C for 16 h to an
optical density at 600 nm (OD600) of 4 to 5. From these cultures, cells were used
to inoculate 0.75 liter of prewarmed main culture medium in the fermentor
(3-liter Applikon) to an initial OD600 of 0.05. Inducer solution (0.5 M) was
prepared by dissolving m-toluate in ethanol.
FIG. 1. Physical map of the expression plasmid pJBphOx. Plasmid
pJBphOx is based on the broad-host-range plasmid pJB658 (Table 1)
and harbors the regulatory Pm/xylS promoter system for expression of
scFv-phOx. Relevant genetic elements: tLPP, transcription terminator;
term, bidirectional transcription terminator; bla, -lactamase; oriT, or-
igin for conjugative transfer; hok-sok, suicide system. For remaining
elements, see the text.
TABLE 1. Bacterial strains and plasmids
Strain or plasmid Descriptiona Referenceor source
E. coli
DH5 General cloning host BRL
RV308 Production strain ATCC 31608
Plasmids
pHOG21-phOx ColE1 replicon harboring scFv-phOx fused to pelB, c-myc, and his6, Apr 15
pHKK ColE1 replicon with lacP/O promoter-operator for recombinant transcription, hok-sok stabilization
elements, Apr
13
pBR322 ColE1 replicon, copy number of 30 per genome, Apr Tcr NEB
pBR322amp pBR322 with deleted bla gene, Tcr This study
pJB658 RK2-based expression vector harboring Pm/xylS regulatory promoter system for expression of cloned
genes, Apr
1
pJB655cop271Cluc Harbors trfA with cop-271 mutation 2
pJB655cop251Mluc Harbors trfA with cop-251 mutation 2
pJBphOx pJB658 with pelB-scFv-phOx-c-myc-his6 fusion gene downstream of Pm, harbors hok-sok suicide system (see text) This study
pJBphOx-271 pJBphOx with 1,853-bp ClaI/XmaI region substituted with corresponding region from pJB655cop271Cluc This study
pJBphOx-251 pJBphOx with 1,853-bp ClaI/XmaI region substituted with corresponding region from pJB655cop251Mluc This study
pJB-251E 8,350-bp pJBphOx-251 NdeI/NotI fragment blunt-ended and religated This study
pJBphOx-271ompA Similar to pJBphOx-271 but with pelB substituted with ompA (see text) This study
pJBphOx-271CSP Similar to pJBphOx-271 but with pelB substituted with consensus signal peptide (see text) This study
pJBphOx-271xylS pJBphOx-271 was digested with AgeI/HpaI, cohesive ends of the large fragment were blunt-ended and
religated (xylS)
This study
pJBphOx-251xylS pJBphOx-271 was digested with AgeI/HpaI, cohesive ends of the large fragment were blunt-ended and
religated (xylS)
This study
a Some of the plasmids are described in the text. Ap, ampicillin; Tc, tetracycline.
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High-cell-density cultivation. All fermentations were performed at 30°C, and
the pH was maintained at 6.8 by addition of 12.5% (vol/vol) NH3. Antifoam
(Adecanol LG-109; Asahi Denka Kogyo, Japan) was added from the start (40
l/liter) and thereafter when needed. The dissolved oxygen was maintained at
20% saturation by automatic adjustments of the stirrer speed or by controlled
feeding of feeding solution 1. The airﬂow rate was initially 0.25 liter/liter of
medium per min and thereafter increased to 1.1 liter/liter of medium per min
throughout the batch phase (see below). Inducer (m-toluate) was added to the
fermentors when cell growth reached an OD600 of 90.
The fermentations were divided into three different phases as follows. (i)
Batch phase. Glucose (22.5 g/liter) was added to the freshly inoculated main
culture medium, and cell growth was continued until all the sugar had been
consumed. (ii) Exponential feeding phase. Growth was controlled to a speciﬁc
growth rate () of 0.2 h1 by feeding with feeding solution 1. Initially the feed
rate of feeding solution 1 was set to 17 g/liter/h and thereafter increased expo-
nentially. This exponential feeding was continued until the stirrer speed reached
1,900 rpm, which is close to the maximal speed of the reactor (2,100 rpm). (iii)
Induction phase. Bacterial growth was controlled by automatic adjustments of
the feeding solution 1 feeding rate (ﬂexible feeding control) so that the dissolved
oxygen and stirring speed were maintained at 20% saturation and 1,900 rpm,
respectively. Throughout the fermentations, pH, dissolved oxygen, feeding rate,
airﬂow, and the molar fraction of CO2 in the exhausted gas were monitored and
recorded.
Determination of the fraction of plasmid-free cells. Cell samples were col-
lected from each high-cell-density cultivation culture and diluted in LB medium
to approximately 1,000 CFU per ml and grown on LA plates without antibiotic
selection at 30°C overnight. From these plates 192 single colonies were picked
with the Genetic QpixII colony picker and individually transferred to 96-well
plates loaded with 140 l of LB medium supplemented with ampicillin (100
g/ml). In addition, each colony was similarly transferred to 96-well plates
without antibiotic selection. The well plates were incubated at 30°C overnight,
and cell growth in individual wells was analyzed by visual inspection. Plasmid-
free cells were detected based on the inability to grow in the selective medium
(observed as clear medium).
Preparation of cell samples for protein product analyses by ELISA and West-
ern blotting. Cell samples (1 ml) were harvested by centrifugation (6,000 	 g, 10
min) and the supernatants (medium) were collected. Periplasmic extraction was
performed essentially as described elsewhere (21) by resuspension of the pellets
in 0.5 ml of 50 mM Tris-HCl buffer, pH 8.0, addition of 0.5 ml of sucrose solution
(40% sucrose containing 2 mM EDTA in 50 mM Tris-HCl buffer, pH 8.0), 1 mg
of lysozyme per ml, and 125 U of benzonase (Merck) per ml. After incubation for
1 h at room temperature with shaking, the suspensions were centrifuged (16,000
	 g, 8 min) and the supernatant (periplasm) and pellet fractions were collected.
Analysis of soluble scFv-phOx was performed by enzyme-linked immunosor-
bent assay (ELISA). Maxisorb plates (Nunc) were coated with phOx-bovine
serum albumin (10 g/ml) in Tris-buffered saline (TBS; 20 mM Tris-HCl, pH 7.5,
150 mM NaCl) overnight at 4°C. All further incubations were performed for 1 h
at room temperature. The wells were washed three times with TBS and blocked
with Blotto (1% skim milk powder and 0.02% antifoam A in TBS). Serial
dilutions of samples in Blotto were then added to the wells, and after washing
three times with TBST (TBS containing 0.05% Tween), anti-c-Myc (Invitrogen)
(1:5,000 in Blotto) was added. The wells were then washed three times with
TBST, and rabbit anti-mouse immunoglobulin-peroxidase (Dako) (1:1,000 in
Blotto) was added. Finally, the wells were washed three times with TBST and
FIG. 2. Volumetric yield of soluble scFv-phOx (top) and cell densities (bottom) at different induction levels (m-toluate) in fermentations with
E. coli RV308 strains harboring pJBphOx (low copy number) and its derivatives pJBphOx-271 (medium copy number) and pJBphOx-251 (high
copy number). In all cases inducer was added at an OD600 of 90. The fermentation with RV308(pJBphOx-271) with 3 mM inducer was terminated
6 h after induction due to foaming and control difﬁculties caused by cell lysis.
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once with TBS, the substrate 2,2-ethylbenzthiasolinesulfonic acid (ABTS) (Bio-
Rad) was added, and the absorbance was read at 405 nm after 10 min.
Analysis of insoluble scFv-phOx in the pellet fractions was performed by
Western blot. The pellets were added to 1 ml of sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE) running buffer (Bio-Rad) and 1-mm
glass beads (KeboLab) and resuspended with vortexing for 1 to 2 min, and
dilution series were made and prepared by boiling in denaturing sample buffer.
The samples were separated by SDS–12.5% PAGE and transferred to a nitro-
cellulose membrane, and the membrane was blocked with Blotto. Recombinant
scFv-phOx was detected with the same antibodies and washing buffers as de-
scribed for the ELISA (above) except that tetramethylbenzidine (Pharmingen)
was used as the substrate. Comparison of band intensities with standard scFv-
phOx of known concentrations was performed and used to estimate the yields of
insoluble scFv-phOx. The scFv-phOx standard used in both the ELISA and
Western blot experiments had been puriﬁed by Ni-Sepharose (Amersham Bio-
science) according to the supplier’s recommendations, and the concentrations of
scFv-phOx were calculated from the absorbance at 280 nm.
RESULTS AND DISCUSSION
Construction and testing of vector pJBphOx for the produc-
tion of soluble scFv-phOx in high-cell-density cultivation of
E. coli. As a model protein in our study we chose scFv-phOx,
which recognizes the hapten 2-phenyloxazol-5-one (phOx)
(17). This important hapten can be easily conjugated to pro-
teins and peptides and the clinical application of scFv-phOx for
selective targeting of imaging and therapeutic agents in vivo
has been demonstrated (8). In a previous report (15) the ex-
pression of 16.5 mg of soluble scFv-phOx/liter was obtained in
E. coli shake-ﬂask cultures with the pelB signal sequence. To
our knowledge, no reports describe scFv-phOx expression un-
der high-cell-density cultivation. The DNA fragment of plas-
mid pHOG21-phOx including the scFv-phOx gene fused to the
c-myc coding region was cloned in frame between the pelB and
the His6 coding sequences of plasmid pHKK (Table 1). From
this construct the region encoding the pelB-scFv-phOx-c-myc-
his6 fusion gene, as well as hok-sok, was excised and cloned
downstream of the Pm promoter of pJB658, yielding plasmid
pJBphOx (Fig. 1). In this way, scFv-phOx is expressed as a
fusion protein targeted for translocation (governed by PelB)
and with C-terminal tags (c-myc-his6) for facilitated detection
and puriﬁcation.
Three parallel fermentors with strain RV308 (pJBphOx)
were run and induced at an OD600 of 90 (about 30 g dry weight
per liter) by adding 0.1, 0.5, and 3.0 mM m-toluate. The pro-
duction rate of soluble scFv-phOx increased as more inducer
was added, and the highest yield was reached 13 h after induc-
tion in all cases (Fig. 2). At 3 mM inducer, 0.48 g/liter of
soluble scFv-phOx was produced, which is comparable to the
results obtained with similar proteins (13). Note that at 13 h
most of the soluble product was localized in the growth me-
dium. This may be due to toxic accumulation of scFv-phOx
in the periplasm, leading to lysis of the producing cells (see
OD600 values in Fig. 2). Representative samples were analyzed
for insoluble product, and the results of these experiments
(Fig. 3) showed that insoluble scFv-phOx yield also increased
as more inducer was added, and it constitutes about 35 to 40%
of the total scFv-phOx (soluble and insoluble) expressed. It
seems probable that these insoluble fractions largely represent
intracellular (not translocated) scFv-phOx proteins, while the
formation of insoluble inclusion bodies in the periplasm could
not be ruled out.
Manipulations with pJBphOx copy number and effects on
recombinant scFv-phOx production levels. Plasmid pJB658
has a copy number of ﬁve to seven per genome (6) and from
the results described above, we predicted that an elevated
scFv-phOx gene dosage may accelerate its expression rate
and thereby possibly lead to even higher levels of soluble
product before cell lysis. To test this hypothesis, the 1,853-
bp ClaI/XmaI fragment (including the trfA gene; see Fig. 1)
was substituted by the corresponding fragment of plasmids
pJB655cop271Cluc and pJB655cop251Mluc (Table 1). The ex-
pected copy numbers of the resulting derivatives, pJBphOx-
271 and pJBphOx-251, should be about three- to fourfold and
eightfold higher than that of the parental plasmid pJB658, re-
spectively (6, 10, 12).
To experimentally verify these copy numbers, we took ad-
vantage of the ability to cotransform our recombinant strains
with an additional replicon, pBR322, with a known copy num-
ber (about 30 per genome in E. coli). The 752-bp EcoRI-PstI
region of pBR322 including the 5 end of the -lactamase gene
was deleted to yield pBR322bla (Table 1), and this plasmid
was introduced into E. coli strains harboring pJB658, pJBphOx,
pJBphOx-271, and pJBphOx-251. The resulting recombinant
strains were grown overnight, and dilution series of the plas-
mids isolated from these cultures were analyzed by gel elec-
trophoresis. Comparison of the band intensities was used to
estimate the copy number of each derivative, and the data
obtained (not shown) were in good agreement with the corre-
sponding expected values as indicated above.
Strain RV308(pJBphOx-271) was tested for production of
scFv-phOx as described above, and the volumetric yield of
soluble scFv-phOx obtained was more than twofold higher (1.2
g/liter) than with pJBphOx (Fig. 2), which is in agreement with
the hypothesis above. Inducer concentrations above 0.1 mM
had no positive effects on the ﬁnal volumetric yield of soluble
scFv-phOx, whereas the production rate in the ﬁrst 3 h was
higher with 0.5 mM. Presumably, a higher production rate
leads to an accelerated release of soluble product into the
FIG. 3. Total volumetric yields of scFv-phOx (soluble and insolu-
ble) at different induction levels in fermentations obtained with RV308
strains harboring pJBphOx (low copy number) and pJBphOx-271 (me-
dium copy number). Strains harboring pJBphOx-251 (high copy num-
ber) were not included in this experiment due to massive loss of this
plasmid prior to induction (see the text).
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culture medium (Fig. 2), and the relative fraction of released
scFv-phOx increased with incubation time after induction. The
maximum cell densities obtained with this strain (OD600 be-
tween 115 and 144) were lower than those obtained with cells
harboring pJBphOx (OD600 of about 200) and decreased
throughout the induction phase (Fig. 2). These observations
support the assumption that high recombinant expression lev-
els lead to rapid toxic accumulation of soluble scFv-phOx in
the periplasm, resulting in cell lysis. In spite of this, a faster
production rate allowed more total product to be made.
Analysis of RV308(pJBphOx-271) cells for insoluble prod-
uct demonstrated that about twofold more insoluble scFv-
phOx was produced with 3 mM compared to 0.1 mM inducer,
even though the amount of soluble product did not increase
(Fig. 3). This probably means that translocation is a limiting
parameter for further improved production of soluble scFv-
phOx under the present conditions, leading to a total produc-
tion of about 2.3 g/liter of scFv-phOx.
In order to analyze the production course of RV308
(pJBphOx-271), the fermentation with this strain was repeated
(ﬁve parallel fermentors) with an induction level of 0.5 mM,
and a typical fermentation course is shown in Fig. 4. The
FIG. 4. Fermentation course of recombinant RV308 (pJBphOx-271) under high-cell-density cultivation. Time courses of bacterial growth
(OD600) and scFv-phOx production (A), exhausted CO2 and feeding rate (B), and stirrer speed and dissolved oxygen (C). Phases 1 and 2 are the
batch and exponential feeding phase of the fermentation, respectively (see Materials and Methods). The time of induction (addition of 0.5 mM
m-toluate) is marked with an arrow. Phases 3a and b represent the initial and prolonged induction phases, respectively. In phase 3a, the ﬂexible
feeding solution 1 control was applied. In phase 3b, constant feeding and stirrer rates were used.
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volumetric yield of soluble scFv-phOx obtained in these
experiments ranged from 1.1 to 1.3 g/liter, demonstrating good
reproducibility. The production of scFv-phOx was initiated
immediately after the induction, and 90% of the soluble scFv-
phOx was produced within 6 h (phase 3a in Fig. 4A). In this
period the cell density reached its maximal value and then
gradually dropped. The drop in optical density was accompa-
nied by a substantial leakage of scFv-phOx to the extracellular
environment, consistent with cell lysis.
In the induction phase (phase 3a, Fig. 4) the feeding rate and
dissolved oxygen are maintained constant at the setpoint val-
ues by automatic adjustments of the feeding rate. The feeding
rate is at its highest level at induction start and is thereafter
automatically gradually reduced to one-third of the maximum
rate during the next 6 h (phase 3a in Fig. 4B). The reduction of
the feeding rate is a consequence of reduced oxygen transfer
capacity in the fermentation broth caused by cell lysis. In order
to push the system to a maximum level of production, the
induction phase was prolonged beyond 6 h (phase 3b in Fig.
4). To control the foaming caused by cell lysis, substantial
amounts of antifoam were added, leading to problems with the
automatic control of the fermentor. The prolonged induc-
tion phase had little impact on the volumetric yield (additional
10%), and the optical density continued to drop throughout
this period.
It could not be excluded that production yield of soluble
scFv-phOx could be further improved by increasing the plas-
mid copy number beyond that of pJBphOx-271. Surprisingly,
irrespective of the inducer concentration applied (data not
shown), the maximum level of soluble scFv-phOx produced
by strain RV308(pJBphOx-251) was only 0.15 g/liter (Fig.
2), which is even lower than that of cells harboring the parental
vector. The reasons for this unexpected result could later be
shown to correlate with extensive plasmid loss before induction
(see below).
Effects of high plasmid copy numbers on plasmid stability
and viability of recombinant cells. It is generally known that
the metabolic burden associated with elevated plasmid copy
numbers and/or high recombinant gene expression levels may
lead to impaired cell growth and concomitant plasmid loss
from recombinant cells (1, 2). We analyzed the various fer-
mentation cultures for plasmid-free cells, and the results of
these experiments demonstrated that the low (pJBphOx) and
medium (pJBphOx-271) copy number vectors were maintained
throughout the fermentation. In contrast, vector pJBphOx-251
was found to be highly unstable, and about 90% of the cells
originally harboring this vector were already plasmid-free prior
to induction.
We speculated that this massive plasmid loss could be due to
high leakage of scFv-phOx expression from Pm, and to test this
we measured soluble scFv-phOx levels in the fermentor cul-
tures prior to induction. Only traces (below 5 mg/liter) of re-
combinant protein were detected with the low-copy number
plasmid pJBphOx, while signiﬁcant levels of soluble scFv-phOx
were detected with pJBphOx-271 (50 mg/ml) and pJBphOx-
251 (120 mg/liter). Considering that the majority of the cells in
the latter culture were plasmid-free under these conditions
(see above), this result suggested that the leakage from Pm in
strain RV308 (pJBphOx-251) is high.
To rule out the possibility that the observed plasmid loss was
somehow caused by the vector itself, the 830-bp region includ-
ing the scFv-phOx-encoding gene was deleted from pJBphOx-
251, yielding construct pJB-251E (Table 1). Recombinant strains
harboring this plasmid were analyzed as described above, and
the results showed that this derivative was 100% stable during
the entire fermentation period, supporting the assumption that
the instability of pJBphOx-251 is related solely to leaky expres-
sion of scFv-phOx.
Both data previously reported by us (6) and the results pre-
sented here suggest that uninduced expression from Pm in-
creases much more than the increase in copy number, and it
has been reported that high XylS levels may accelerate consti-
tutive transcription from Pm (24). To investigate this, we de-
leted the 776-bp region including the 5-terminal region of xylS
and upstream sequences of the copy-up derivatives pJBphOx-
271 and pJBphOx-251, yielding plasmids pJBphOx-271xylS
and pJBphOx-251xylS, respectively (Table 1). Recombinant
RV308 strains harboring these constructs produce only 5 and
30 mg/liter of soluble scFv-phOx, respectively, under nonin-
duced conditions, which is far below the levels detected with
the parental vectors (see above). Interestingly, no plasmid-free
cells were detected in these cultures. Together, these results
indicate that high basal expression from Pm present in a high-
copy-number vector is mediated solely by the simultaneous
presence of a correspondingly increased copy number of the
xylS gene. By controlling the xylS expression level from a reg-
ulated promoter, the problems with plasmid loss at high copy
numbers might be avoided, and one might possibly also envi-
sion improved yields of scFv-phOx or other protein products of
interest.
Plasmid pJBphOx-271 is stably maintained under high-cell-
density cultivation without antibiotic selection. The numbers
of generations obtained in the preculture medium and the
main culture medium under the conditions used in the present
study are 9 and 11 to 12, respectively. To further test the sta-
bility of our expression vectors, high-cell-density cultivation
fermentation of RV308(pJBphOx-271) was performed without
antibiotic selection. Moreover, to obtain conditions compara-
ble to a large-scale fermentation, preculture medium cultiva-
tion was repeated twice before transfer to the main culture me-
dium, resulting in approximately 30 generations for the three
successive cultivations. As a control, a parallel experiment was
run with the standard amount of ampicillin (0.1 g/ml) added to
the media. The results of these experiments demonstrated that
pJBphOx-271 was stably maintained during the entire fermen-
tations and the production levels of soluble scFV-phOx were
also similar (data not shown). The hok-sok suicide elements
have been shown to signiﬁcantly enhance the stability when
present on other replicons (20), but their direct contribution to
the stability observed in our constructs remains unknown. In
any case, the option of running industrial processes without
antibiotics in the production medium confers both economic
and regulatory advantages.
Different signal sequences display considerable effects on
the expression levels of recombinant scFv-phOx. In E. coli it
has been shown that the ﬁrst codons at the 5 end of a struc-
tural gene may have a severe impact on translation initiation
(27). In our constructs it is likely that the 5-terminally fused
pelB sequence, which is of bacterial origin, contributes to ef-
fective expression of scFv-phOx in addition to governing trans-
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location. Although the majority of the scFv-phOx expressed in
our strains is presumably exported, we could not rule out that
translocation is limiting for higher yields of soluble scFv-phOx
under the conditions tested. In order to test this, we applied
the two alternative signal sequences ompA and consensus sig-
nal peptide. The former has been used for effective transloca-
tion of various recombinant proteins in E. coli (22), whereas
consensus signal peptide was designed here based on published
sequence alignments of several bacterial signal peptides (18).
Both signal sequences were made synthetically (see Materials
and Methods) and used to substitute pelB in pJBphOx-271,
yielding derivatives pJBphOx-271ompA and pJBphOx-271CSP
(Table 1).
Recombinant strains harboring these plasmids produced sol-
uble scFv-phOx at signiﬁcantly lower yields (0.15 and 0.43
g/liter, respectively) than the strain harboring the parental
vector. We proceeded to measure insoluble scFv-phOx in these
samples, and the data showed that these levels were also low
(0.10 g/liter for OmpA and 0.17 g/liter for consensus signal
peptide). Together our results indicate that the overall scFv-
phOx expression levels obtained with OmpA and consensus
signal peptide are low compared to those obtained with PelB.
Thus, our results show that the choice of signal sequence has a
strong impact on both the translocation and expression level of
recombinant scFv-phOx under the conditions tested.
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Strong Stimulation of the Total Expression Levels of Three Tested
Medically Important Proteins during High-Cell-Density
Cultivations of Escherichia coli
H. Sletta,1 A. Tøndervik,2 S. Hakvåg,2 T. E. Vee Aune,2 A. Nedal,2 R. Aune,1 G. Evensen,3
S. Valla,2 T. E. Ellingsen,1 and T. Brautaset1*
SINTEF Materials and Chemistry, Department of Biotechnology, SINTEF, Trondheim, Norway1; Department of Biotechnology,
Norwegian University of Science and Technology, Trondheim, Norway2; and Alpharma AS, Oslo, Norway3
Received 31 July 2006/Accepted 18 November 2006
Genetic optimizations to achieve high-level production of three different proteins of medical importance for
humans, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon alpha 2b (IFN-2b), and
single-chain antibody variable fragment (scFv-phOx), were investigated during high-cell-density cultivations of
Escherichia coli. All three proteins were poorly expressed when put under control of the strong Pm/xylS
promoter/regulator system, but high volumetric yields of GM-CSF and scFv-phOx (up to 1.7 and 2.3 g/liter,
respectively) were achieved when the respective genes were fused to a translocation signal sequence. The choice
of signal sequence, pelB, ompA, or synthetic signal sequence CSP, displayed a high and speciﬁc impact on the
total expression levels for these two proteins. Data obtained by quantitative PCR conﬁrmed relatively high in
vivo transcript levels without using a fused signal sequence, suggesting that the signal sequences mainly
stimulate translation. IFN-2b expression remained poor even when fused to a signal sequence, and an
alternative IFN-2b coding sequence that was optimized for effective expression in Escherichia coli was
therefore synthesized. The total expression level of this optimized gene remained low, while high-level pro-
duction (0.6 g/liter) was achieved when the gene was fused to a signal sequence. Together, our results
demonstrate a critical role of signal sequences for achieving industrial level expression of three human
proteins in E. coli under the conditions tested, and this effect has to our knowledge not previously been
systematically investigated.
Human cytokines are proteins that promote immune re-
sponses, and they have a broad range of medical uses, such as
treatment of microbial and viral infections and vaccination
against cancer. In 2004, the global cytokine market was 6.5
billion U.S. dollars, and according to a Research and Markets
report, the demand for existing cytokines is expected to grow
signiﬁcantly in the next years (http://www.researchandmarkets
.com/reports/314808/). Thus, cytokines are needed in large
quantities, and the development of high-cell-density cultiva-
tions (HCDC) has led to production at high volumetric yields
of such pharmaceutically important proteins in heterologous
hosts like Escherichia coli. Despite the many advantages of this
organism, high-level heterologous expression is not routinely
achieved, typically due to biased codon usage, gene product
toxicity, low gene product solubility, mRNA secondary struc-
ture formation, and low mRNA stability (15, 26). The broad-
host-range plasmid pJB658 harbors the inducible Pm/xylS pro-
moter/regulator elements for recombinant expression of cloned
genes in a wide range of gram-negative bacteria (3, 4). We
recently modiﬁed this plasmid to express high volumetric yields
of secreted recombinant single-chain antibody variable frag-
ment (scFv-phOx) during HCDC of E. coli (26). To obtain
secretion, we added (at the DNA level) a signal sequence at
the N terminus of scFv-phOx, a method that is commonly used
if intracellular production is undesired.
The important cytokine granulocyte-macrophage colony-
stimulating factor (GM-CSF) is one of four speciﬁc glycopro-
teins that stimulate generation of the white blood cells granu-
locytes and macrophages (18). Recombinant GM-CSF has
been expressed in bacterial, yeast, and mammalian cells and is
now produced for clinical uses. This protein has greatly re-
duced the infection risk associated with bone marrow trans-
plantation (19). GM-CSF produced recombinantly in E. coli
ends up in inclusion bodies (IBs) and has certain drawbacks,
including complex processing, low speciﬁc activity, and poor in
vitro renaturation (2). The GM-CSF product obtained as an IB
has an added methionine at the N terminus that leads to
stimulation of antibody production in the human body, hence
inﬂuencing the therapeutic value (8, 33). Interferon alpha 2b
(IFN-2b) belongs to the IFN family of cytokines, which can
induce antiproliferative, immunomodulatory, and potent anti-
viral activities against a wide range of mammalian viruses (7).
IFN-2b is used to treat several diseases, including some types
of cancer and hepatitis, in particular hepatitis C. Since it can
increase the intensity of antigen expression on certain tumors,
IFN-2b has a potential for use in diagnostics and therapeutics
(20). As for GM-CSF, IFN-2b has also been expressed re-
combinantly into active form in E. coli (28).
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In this report, we describe the use of the pJB658-based
expression system (26) to produce GM-CSF, IFN-2b, and
scFv-phOx both intracellularly (lacking signal sequences) and
through secretion (with signal sequences) during HCDC. Sur-
prisingly, we found that the presence of signal sequences very
strongly stimulated not only secretion but also the total pro-
duction levels of all three of these proteins. Such effects are to
our knowledge not commonly referred to in the scientiﬁc lit-
erature but should be of signiﬁcant importance in this ﬁeld of
biotechnology.
MATERIALS AND METHODS
Strains, DNA manipulations, and growth conditions. E. coli strains used in this
study were as follows: DH5 (BRL) was used as a cloning host, while RV308
(ATCC 31608) was the standard recombinant production strain used for HCDC
of E. coli. Strain BL21(DE3) (Stratagene) is deﬁcient in the OmpT and Lon
proteases and was used as an alternative test strain for recombinant protein
production. BL21-CodonPlus (DE3)-RIPL (Stratagene) carries argU, ileY, and
leuW genes encoding tRNA molecules that recognize rare codon triplets. ATCC
67979 and ATCC 53157 carry plasmids with the IFN-2b and GM-CSF coding
regions, respectively (ATCC). Standard cloning experiments were performed as
described elsewhere (23), and recombinant E. coli strains were grown at 37°C in
liquid Luria-Bertani (LB) medium or on solid LB agar plates. For small-scale
production analyses, cells were grown at 30°C with shaking (225 rpm; orbital
moment, 2.5-cm amplitude) in 250-ml bafﬂed shake ﬂasks containing 40 ml HiYe
medium, which is composed as follows: Na2HPO42H2O, 8.6 g/liter; KH2PO4, 3
g/liter; NH4Cl, 1 g/liter; NaCl, 0.5 g/liter; glucose, 2 g/liter; glycerol, 10 g/liter;
yeast extract, 10 g/liter; MgSO4, 2.5 mM; Fe(III)-citrate, 250 M; H3BO3, 49
M; MnCl2, 79 M; EDTA, 23 M; CuCl2, 9 M; Na2MoO4, 10 M; CoCl2, 11
M; and Zn-acetate, 36 M. Site-speciﬁc mutagenesis was performed by using a
QuickChange site-directed mutagenesis kit from Stratagene according to the
manufacturer’s instructions. Oligonucleotides used in this study are listed in
Table 1. The deﬁned preculture and the main culture media were prepared as
described previously (26). When appropriate, the media were supplemented with
ampicillin (100 g/ml) and chloramphenicol (10 g/ml). Design of the optimized
IFN-2bS gene was performed by GenScript, a 501-bp double-stranded DNA
fragment encoding this sequence was synthesized (GeneScript), and unique NdeI
and NotI restriction sites were introduced at the 5 and 3 ends, respectively, and
cloned into the corresponding sites of pUC57, yielding pUC57IFN-S.
Vector constructions. All oligonucleotide primers used hereunder are
listed in Table 1, and all expression vectors constructed were veriﬁed by DNA
sequencing.
pJBphOx-271d. Two unique restriction sites, SacI and AgeI, were introduced,
ﬂanking the xylS coding region of plasmid pJT19bla (31), by site-directed mu-
tagenesis with the mutagenic oligonucleotide pairs sacI-F and sacI-R and ageI-F
and ageI-R, respectively. The 1,025-bp SacI-AgeI fragment was subcloned into
the corresponding sites of pLITMUS28 (New England Biolabs). The NcoI re-
striction site in the xylS gene then was speciﬁcally mutated in the latter construct
with the mutagenic oligonucleotides ncoI-F and ncoI-R, yielding pTA4-NcoI. In
parallel, plasmid pJB655cop271 (3) was digested with XmaI-BseRI, and the
cohesive ends of the vector fragment were blunted and religated. The unique
NdeI site of the trfA gene was then speciﬁcally mutated with the mutagenic
oligonucleotides ndeI-F and ndeI-R, yielding plasmid pTA20. The 1,171-bp
ClaI-SexA1 fragment of pTA20, including the mutated trfA gene, and the 339-bp
HpaI-MunI fragment of pTA4-NcoI, including the xylS gene, were isolated and
used to substitute for the corresponding fragments of vector pJBphOx-271 (26),
yielding the cassette cloning and expression vector pJBphOx-271d.
pGM29. The coding region of the mature GM-CSF gene was PCR cloned from
total DNA isolated from E. coli ATCC 53157 by using primers gm-1F and
gm-1R. The resulting DNA fragment was end digested with NdeI and NotI, and
the 389-bp fragment was used to substitute with the corresponding scFv-phOx
fragment of pJBphOx-271d, yielding pGM29 (expressing GM-CSF without signal
sequence).
pGM29pelB. The coding region of the mature GM-CSF gene was PCR cloned
from E. coli ATCC 53157 total DNA with the primers gm-2F and gm2R. The
resulting DNA fragment was end digested with NcoI and NotI, and the 390-bp
fragment was used to substitute for the corresponding scFv-phOx fragment of
plasmid pJBphOx-271d, yielding pGM29pelB (expressing GM-CSF with pelB
signal sequence).
pGM29ompA and pGM29CSP. The DNA fragments with ompA and CSP
coding sequences were prepared by annealing of synthetic oligonucleotides as
described previously (26) and used to substitute for the corresponding NdeI-
NcoI pelB fragment of pGM29pelB, to yield pGM29ompA and pGM29CSP,
respectively (expressing GM-CSF with ompA and CSP signal sequences, respec-
tively).
pAT65. The scFv-phOx-cmyc-his6 coding region of pJBphOx was PCR ampli-
ﬁed by using the primers phox-1F and phox-1R and end digested with NdeI-NotI,
and the resulting 770-bp fragment was used to substitute for the corresponding
fragment of plasmid pGM29pelB, yielding pAT65 (expressing scFv-phOx with-
out signal sequence).
pIFN30pelB. The IFN-2b coding region was PCR ampliﬁed from DNA
isolated from E. coli strain ATCC 67979 by using the primers IFN-1F and
IFN-1R and was end digested with NcoI-NotI, and the 504-bp fragment was
ligated into the corresponding sites of pGEM-5zf (Promega). From the resulting
plasmid, the 504-bp NcoI-NotI insert was isolated and used to substitute for the
corresponding region of pGM29pelB, yielding pIFN30pelB (expressing IFN-2b
with pelB signal sequence).
pIFN30. The IFN-2b coding region was PCR ampliﬁed from DNA isolated
from strain ATCC 67979 by using the primers IFN-2F and IFN-1R and was end
digested with NdeI-NotI, and the 501-bp fragment was ligated into the corre-
sponding sites of pGEM-5zf. From the resulting plasmid, the 501-bp NdeI-NotI
insert was isolated and used to substitute for the corresponding fragment of
pGM29pelB, yielding pIFN30 (expressing IFN-2b without signal sequence).
pIFN30S and pIFN30SpelB. The 501-bp NdeI-NotI fragment of plasmid
pUC57IFN-S (see above) was used to substitute for the corresponding fragment
of plasmid pGM29pelB, yielding pIFN30S (expressing IFN-2bS without signal
sequence). The IFN-2bS insert was PCR ampliﬁed from pIFN30S by using
primers IFN-3F and IFN-2R and was end digested with NcoI-NotI, and the
504-kb fragment was used to substitute for the corresponding fragment of
pGM20pelB, yielding pIFN30SpelB (expressing IFN-2bS with pelB signal se-
quence).
Production analyses in shake ﬂask cultures. Overnight cultures of recombi-
nant cells were diluted into fresh prewarmed HiYe medium (100 ml) to an
optical density at 600 nm (OD600) of 1, and cell growth was continued to an
OD600 of 3. At this point, the cultures were induced by adding m-toluic acid (0.5
mM) and cell growth was continued for 4 h (OD600 
 10 to 15) before cell
harvesting. Preparation of cell samples and product detections were performed
as described below.
Production analyses in HCDC. Preparation of fermentation inoculum and
HCDC of recombinant E. coli strains was performed as described previously
(26). The cell cultures were induced at an OD600 of 100, and cell growth was
TABLE 1. Oligonucleotides used in this study
Name Sequence (5–3)a
sacI-F...............CTCTTATTTTAATGTGAGCTCCTTGGTGTGAT
GTAG
sacI-R ..............CTACATCACACCAAGGAGCTCACATTAAAAT
AAGAG
ageI-F ..............GCGATGCCAACCGGTCCCTTCTTCGGC
ageI-R..............GCCGAAGAAGGGACCGGTTGGCATCGC
ncoI-F ..............GGCGTGGCCATGGCCAGGAGCAC
ncoI-R .............GTGCTCCTGGCCATGGCCACGCC
ndeI-F..............CTACACGAAATTCATCTGGGAGAAGTACCGC
ndeI-R .............GCGGTACTTCTCCCAGATGAATTTCGTGTAG
gm-1F ..............TTTTCATATGGCACCCGCCCGCTCGCC
gm-1R..............TTCGGATCCAGCGGCCGC
gm-2F ..............CACCATGGCTGCACCCGCCCGCTCGCC
gm-2R..............GCGCGGCCGCCTCCTGGACTGGCTCCC
phox-1F ...........TTTTCATATGGCCCAGGTGCAGCTGGTGCAGT
CTGGAG
phox-1R...........ATCAGCTTTTGTTCGGATCCAGCGGCCGCACC
IFN-1R ............TTTTCCATGGCTTGTGATCTGCCTCAAACCC
IFN-1R ............TTTTGCGGCCGCTTCCTTACTTCTTAAACTTTC
TTGC
IFN-2F.............TTTTCATATGTGTGATCTGCCTCAAACCC
IFN-3F.............TTTTCCATGGCTTGCGATCTGCCGCAGACCC
IFN-2R ............CAGCTTTTGTTCGGATCCAGCGGCCGCTTCT
TTGC
a Relevant restriction sites used for cloning of PCR products are underlined.
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continued for 4 to 6 h, typically corresponding to an OD600 of 180 to 200. All
quantitative protein data given from the high-yielding HCD fermentations are
based on values from at least two independent cultivations.
Preparation of cell samples for protein product analyses by ELISA and West-
ern blotting. Cell sample preparations of medium (designated as S1 phase),
soluble (designated as S2 phase), and pellet (designated as P2 phase) fractions
for production analyses, and Western analyses of recombinant IFN-2b, scFv-
phOx, and GM-CSF proteins, were performed as described elsewhere (26).
Recombinant soluble GM-CSF was quantiﬁed by using a human GM-CSF en-
zyme-linked immunosorbent assay (ELISA) set kit from BD Biosciences, in
accordance with the manufacturer’s instructions. Puriﬁed scFv-phOx protein
served as a standard in all cases.
N-terminal sequencing of recombinant proteins. Samples (0.2 ml) collected
from the soluble fractions (see above) of the cell extracts were puriﬁed by using
the Ni-nitrilotriacetic acid spin protocol from QIAGEN under denaturating
conditions, in accordance with manufacturer’s instructions. About 15 mg of
puriﬁed protein (judged by using the Bio-Rad method) was then subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and concomitant
Western blotting, as described above. The membrane was stained with Coomas-
sie brilliant blue R250, and the band corresponding to the desired mass was
excised and used as a template for the sequencing which was performed by the
Biotechnology Centre of Oslo, Norway (K. Sletten and S. Kjæraas).
Isolation of total RNA, reverse transcription, and quantitative PCR. The
experiments hereunder were performed essentially as described previously (9).
Cell samples (0.1 ml) were harvested from the HCDC fermentations at an OD600
of 130 to 160, diluted in fresh medium to an OD600 of 10, and immediately
treated with RNA Protect (QIAGEN). Total RNA was isolated by using an
RNAqueous kit (Ambion) according to the manufacturer’s instructions, and 3 g
of the obtained material was treated with a DNA-free kit (Ambion) and used as
template for cDNA synthesis by using a ﬁrst-strand cDNA synthesis kit (Amer-
sham). The quantitative PCR proﬁle was as follows: segment 1 (1 cycle), 95°C at
10 min; segment 2 (40 cycles), 95°C for 30 s, 55°C for 60 s, and 68°C for 30 s; and
segment 3 (1 cycle), 95°C for 60 s, 55°C for 30 s, and slowly up to 95°C (disso-
ciation curve). The primers used are listed in Table 1. We used the iTaq SYBR
Green Supermix with Rox (Bio-Rad), and ampliﬁcation reaction mixtures con-
tained 5 l of diluted cDNA templates and 3 pmol of each primer in a ﬁnal
volume of 20 l. The PCR products were detected by monitoring the increase in
ﬂuorescence by using an Mx3000P cycler system (Stratagene). Thresholds (CT)
were set which intersected the ampliﬁcation curves in the linear region of the
semilogarithmic plots, and inspection of the dissociation curves conﬁrmed neg-
ligible levels of primer self-hybridizations. Ampliﬁcation of the -lactamase gene
present on the expression vector was used for sample normalization. All exper-
iments were performed in three parallels.
In silico analysis of mRNA secondary structures. The deduced transcripts of
the gene variants were analyzed for secondary structures by using the program
MFOLD (34) (http://www.bioinfo.rpi.edu/applications/mfold/old/rna/). Regions
covering about 50 to 60 bp from the Pm transcription start point (22), including
the translation initiation codon and its ﬂanking regions, were used for these
analyses.
RESULTS
Construction of the cloning and cassette expression vector
pJBphOx-271d. Plasmid pJBphOx-271, used previously to pro-
duce scFv-phOx, was modiﬁed (generating pJBphOx-271d;
Fig. 1) to facilitate the construction of the expression cassettes
required for this study. In this new vector, the gene encoding
scFv-phOx can easily be substituted by any gene of interest by
a one-step cloning procedure, using either the NdeI/NotI sites
(no signal sequence) or the NcoI/NotI sites (DNA sequence
encoding the pelB signal sequence fused in frame to the 5-
terminal end). The coupled afﬁnity detection sequence c-myc-
his6 is fused to the 3-terminal end of the cloned gene. The
complete fusion genes are at the 5 end, with or without a
secretion signal sequence, placed in frame under translational
control of the ribosome binding sequence (rbs) region and
under transcriptional control of the tightly controlled and in-
ducible Pm/xylS promoter/regulator system (3, 4) of the plas-
mid. Recombinant genes to be expressed, the type of signal
sequence (pelB, ompA, or CSP) used, or the vector copy num-
ber (see reference 26) can thus easily be changed by one-step
cloning procedures.
GM-CSF and IFN-2b are not expressed at detectable levels
in pJBphOx-271d in the absence of a signal sequence. In
contrast to protein scFv-phOx, GM-CSF and IFN-2b do not
contain disulﬁde bridges. Consequently, the translocation of
these two proteins to the periplasm to obtain correct product
folding was not considered necessary, and we therefore chose
to express them without the use of a secretion signal sequence.
The gene encoding scFv-phOx was therefore substituted with
those of GM-CSF and IFN-2b as NdeI/NotI fragments (Fig.
1), generating plasmids pGM29 and pIFN30, respectively.
These plasmids were transformed into the E. coli production
host strain RV308, and the resulting transformants were ini-
tially subjected to production analyses in shake ﬂask cultures.
Western blot analyses of both the soluble (S1 and S2) and the
pellet (P2) fractions (see Materials and Methods) of the cells
showed that no recombinant product could be detected (below
1 mg/liter) from any of the two strains. To rule out the possi-
bility that the poor result is linked to the RV308 host strain
used, we also analyzed the production in the protease-modiﬁed
E. coli strain BL21(DE3) (see Materials and Methods). No
detectable production was observed in this host either, indi-
cating that the low production levels observed are not a strain-
speciﬁc property.
The production levels of GM-CSF and scFv-phOx, but not of
IFN-2b, are dramatically stimulated by 5-terminal fusion of
the pelB signal sequence. We previously demonstrated that the
choice of signal sequence used, pelB, ompA, or CSP, is impor-
tant to achieve both effective translocation and high total ex-
pression level of scFv-phOx, and the best overall result was
obtained with pelB (26). Based on the somewhat surprising
results obtained with proteins GM-CSF and IFN-2b (see
above), it was of interest to also test the impact of expressing
scFv-phOx protein without the use of a secretion signal se-
quence. We therefore constructed vector pAT65 which has no
signal sequence and with the scFv-phOx coding sequence po-
sitioned in frame with the relevant translational start codon of
the vector (see Materials and Methods). Production analysis of
the S1, S2, and P2 fractions of strain RV308(pAT65) showed
that no recombinant product (below 1 mg/ml) could be de-
tected. This result showed that scFv-phOx is dependent on a
signal sequence to be effectively expressed under these condi-
tions, suggesting that efﬁcient expression of GM-CSF and IFN-
2b might also potentially be obtained by fusing the corre-
FIG. 1. Physical map of part of the cassette cloning and expression
vector pJBphOx-271d. Relevant restriction sites useful for gene clon-
ing with and without a fused signal sequence, as well as for shifting out
pelB with ompA and CSP, are indicated (see also Materials and Meth-
ods). tLPP, transcriptional terminator.
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sponding gene sequences to the pelB sequence. Strains (RV308)
containing the resulting plasmids pGM29pelB (expressing
GM-CSF with pelB) and pIFN30pelB (expressing IFN-2b
with pelB) were therefore subjected to production analysis in
shake ﬂask cultures. Interestingly, a substantial level (about 50
mg/liter) of recombinant GM-CSF protein was now produced,
while no detectable IFN-2b production could be detected.
Here we show that the poor IFN-2b production observed is
partly due to unfavorable codon usage in the IFN-2b coding
region (see below). Under HCDC conditions, high-level pro-
duction of GM-CSF was achieved (0.8 g/liter) and about 50%
of the detected protein was present as soluble product (Fig. 2
and Table 2). This result therefore clearly indicated that efﬁ-
cient GM-CSF expression is (similar to scFv-phOx) dependent
on a fused signal sequence to be effectively expressed, under
the conditions tested.
Exchange of pelB with the alternative signal sequences CSP
and ompA caused up to twofold-improved GM-CSF production
levels. To analyze the effect of using different signal sequences
on the expression level of GM-CSF, the pelB coding region
of plasmid pGM29pelB was substituted with the ompA and
CSP coding regions to yield constructs pGM29ompA and
pGM29CSP, respectively. Production analysis during HCDC
with cells harboring these two constructs (Fig. 2 and Table 2)
demonstrated that the highest total production level (1.7 g/li-
ter) was obtained by using ompA. Interestingly, the rankings of
signal sequences with respect to the highest total expression
level achieved for GM-CSF and scFv-phOx are very different
(Fig. 3). As observed with scFv-phOx, the fraction that is sol-
uble relative to the total GM-CSF produced remained rela-
tively constant, irrespective of the total expression level (about
50 to 60%).
Unfavorable codon usage partly contributes to the poor ex-
pression of IFN-2b. The strong stimulatory effects of secre-
tion signal sequences on the expression levels for both scFv-
phOx and GM-CSF were not observed with IFN-2b (see
above), and we wanted to identify the reasons for this. First,
the respective coding DNA sequences were analyzed and com-
pared (Table 3). All three genes are relatively small (between
378 and 777 nucleotides), and the total numbers of rare codons
are also similar (between 10 and 13). We also noticed that the
IFN-2b gene has a low GC content compared to those of both
the GM-CSF and scFv-phOx genes, and the possible relevance
of this for expression is unknown. To experimentally test the
impact of the rare codons on gene expression, we transformed
the vectors pIFN30 (no signal sequence) and pIFN30pelB
FIG. 2. Images of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (top panels) and the corresponding Western blots (bottom panels)
of insoluble fractions of recombinant RV308 strains producing GM-CSF and IFN-2b proteins, during HCDC. The type of signal sequence used,
pelB, ompA, CSP, or no signal sequence, is indicated in each lane, and the recombinant proteins are indicated with arrows. Numbers on the left
side of each image represent molecule sizes in kilodaltons.
TABLE 2. Expression data of GM-CSF-producing strains
during HCDCa
Plasmid Signalsequence OD600
b
Protein product
mRNAe
Solublec Insolubled
pGM29 None 183 BDf BD 1.0	  0.1	
pGM29pelB pelB 190 0.39  0.03g 0.4  0.05 3.0	  0.5	
pGM29CSP CSP 181 0.80  0.11 0.7  0.15 3.4	  0.3	
pGM29ompA ompA 183 0.70 0.09 1.0  0.25 8.0	  0.9	
a Recombinant cell cultures were grown in the fermentors to an OD600 of 100
before inducer was added (see Materials and Methods), and the maximum
protein product and corresponding mRNA levels are given.
b OD600 values obtained in the fermentors at the time of maximum product
yields.
c Soluble protein was determined by using ELISA as described in Materials
and Methods.
d Insoluble protein was quantiﬁed from dilution series of insoluble fractions
subjected to Western blotting as shown in Fig. 2.
e The GM-CSF mRNA levels were measured by quantitative PCR as described
in Materials and Methods; the mRNA level of cells harboring plasmid pGM29
(no signal sequence) was deﬁned here as 1.0	.
f Below detection limit (below 1 mg/ml).
g Values for soluble and insoluble proteins are in g/liter.
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(pelB signal sequence) into the E. coli strain BL21-CodonPlus
(DE3)-RIPL, which can effectively translate the low-usage
codons AGG/AGA, AUA, and CUA (see Materials and Meth-
ods). The resulting recombinant strains were subjected to
shake ﬂask production analyses as described above. Interest-
ingly, substantial IFN-2b production (about 30 mg/liter) was
achieved with cells harboring pIFN30pelB, while low produc-
tion was still obtained (about 5 mg/liter) with cells harboring
pIFN30 (Table 4). These results conﬁrm our assumption that
the codon usage of IFN-2b is one major reason for the poor
expression obtained for this protein in strain RV308. They also
indicate that expression of this gene, as observed for scFv-
phOx and GM-CSF genes, is strongly stimulated by the pelB
secretion signal sequence under these conditions.
Design and construction of a synthetic IFN-2b gene, des-
ignated IFN-2bS, useful for high-level IFN-2b production.
To optimize the coding sequence of IFN-2b for high expres-
sion in our preferred production host strain RV308 (26), the
entire gene sequence was completely redesigned through com-
plete gene synthesis (using computer software; see Materials
and Methods). The synthetic gene is 80.4% identical to its
parental version and has 99 nucleotide substitutions affecting
77 of its codons (46% of all its codons), still maintaining the
original sequence of the protein product. The GC content of
the synthetic gene is 53.6% compared to 48.4% of the original
gene, and it has no rare codons (Table 3). It was of interest to
test if this optimized IFN-2bS gene could be efﬁciently ex-
pressed without a signal sequence in RV308, and it was there-
fore used to substitute for IFN-2b in plasmid pIFN30, yield-
ing plasmid pIFN30S. Interestingly, shake ﬂask experiments
with RV308(pIFN30S) showed that the IFN-2b production
was still below the detection level (Table 4). Therefore, we
constructed the analogous vector pIFN30SpelB containing
pelB and a similar analysis of RV308 harboring this plasmid
showed that the IFN-2b protein was then produced at about
40 mg/liter (Table 4). Strains RV308(pIFN30S) and RV308
(pIFN30SpelB) were then analyzed during HCDC, and a total
of 0.6 g/liter of IFN-2b protein was produced with plasmid
pIFN30SpelB, while no product was detected with plasmid
pIFN30S (Fig. 2 and 3). Interestingly, all recombinant IFN-2b
production was present as IBs. As a control in these HCDC
experiments, we also included strain RV308(pIFN30pelB) with
the original IFN-2b gene fused to pelB, and the total production
level of this strain was found to be low, as expected (about 0.04
g/liter). Thus, the optimized IFN-2bS DNA coding sequence
could be used to achieve a high production level for IFN-2b
protein in E. coli RV308, but only provided that a signal sequence
is fused to the 5-terminal end of the coding region.
Quantitative PCR analyses suggest that both the transcript
levels and translation efﬁciencies are higher when using signal
sequences. To increase the understanding of how the signal
sequences stimulate gene expression, we analyzed a selection
of our recombinant strains under relevant production condi-
tions by using quantitative real-time PCR. The rankings of
GM-CSF transcript levels in the four different GM-CSF-pro-
ducing strains tested were similar to the corresponding rank-
ings of total protein production levels (Table 2). Interestingly,
the transcript level of RV308(pGM29), which has no signal
FIG. 3. Production levels of scFv-phOx and GM-CSF as a function
of different signal sequences, and no signal sequence, during HCDC.
The scFv-phOx production data presented here were imported from
our previous study (26). Both soluble and insoluble fractions are given
for all recombinant strains tested. Production analysis of scFv-phOx
without using a signal sequence resulted in no detectable product (see
the text) and was therefore not performed during HCDC. Production
of INF-2b was not tested with signal sequences ompA and CSP.
TABLE 3. Comparison of coding sequences of recombinant genes
used in this study
Gene
product
Gene length
(nucleotides)
GC content
(%)
No. of rare
codonsa
scFv-phOx 777 55.0 12
GM-CSF 378 57.7 10
IFN-2b 495 48.4 13
IFN-2bS 495 53.6 0
a Rare codons are as follows. scFv-phOx: arginine, CGA (3 codons), AGA (4
codons), and AGG (1 codon); leucine, CTA (1 codon); isoleucine, ATA (1
codon); and proline, CCC (2 codons). GM-CSF: arginine, CGG (2 codons) and
AGA (1 codon); leucine, CTA (1 codon); and proline, CCC (6 codons). IFN-
2b: arginine, AGG (4 codons) and AGA (5 codons); leucine, CTA (1 codon);
isoleucine, ATA (1 codon); and proline, CCC (2 codons).
TABLE 4. Production levels of recombinant IFN-2b protein
obtained in shake ﬂasks by using original and synthetic
genes and in different genetic backgrounds
Plasmid
Production level (mg/liter)
RV308a BL21(DE3) BL21-CodonPlus(DE3)-RIPL
pIFN30 BDb BD 5  2
pIFN30S BD
pIFN30pelB BD BD 30 9
pIFN30SpelB 40  12
a The three different E. coli host strains used, RV308, BL21(DE3), and BL21-
CodonPlus (DE3)-RIPL, are described in Materials and Methods. For IFN-2b
production levels with host RV308 under HCDC, see Fig. 2 and 3. All experi-
ments were run in three parallels, and the standard errors are indicated.
b BD, below detection limit (under 1 mg/liter).
910 SLETTA ET AL. APPL. ENVIRON. MICROBIOL.
sequence and produces no detectable GM-CSF protein, is only
about threefold lower than the transcript levels detected when
using pelB or CSP. This result implies that the low GM-CSF
expression level of this strain is largely due to inefﬁcient trans-
lation and not poor transcription. In bacteria, transcription and
translation are tightly coupled in time and space, and for a
given mRNA, high translational activity can protect the mRNA
from degradation due to ribosome occupancy, which in turn
contributes to more translational activity. We therefore believe
that our data indicate that signal sequences can increase both
the transcript levels and the translation efﬁciencies of the genes
to which they have been fused.
N-terminal sequencing of recombinant proteins conﬁrmed
that the signal sequences are cleaved off in vivo. To make sure
that the secretion signal sequences were cleaved off in vivo, the
soluble fractions (S1 and S2) of the fermented cultures of
recombinant strains RV308(pGM29ompA) and RV308(pGM2
9CSP) were subjected to Western analysis and the desired
proteins were excised and subjected to N-terminal sequencing.
The results of these experiments conﬁrmed that the recombi-
nant products in both samples are equivalent to the primary
sequence of the GM-CSF mature protein (data not shown),
implying that the signal sequences and the initial Met residue
were correctly cleaved off.
DISCUSSION
Secretion signal sequences are generally used in recombi-
nant gene expression for the purpose of achieving transloca-
tion of the protein of interest. It is well-known that there exists
no general rule guiding the choice of signal sequence that will
maximize the level of translocation of any particular protein,
and a trial-and-error type of approach is therefore commonly
used (6). Here we demonstrate an unexpected and important
role of signal sequences in strongly stimulating the levels of
expression for three different proteins of human origin during
HCDC in E. coli. By selecting the appropriate signal se-
quences, we achieved total product yields of up to 2.3 g/liter
(Fig. 3), which is sufﬁciently high to be commercially interest-
ing. In gram-positive Lactobacillus lactis, it has been showed
that protein secretion can be an effective way to increase the
overall expression level of several heterologous proteins (14).
It has been suggested that this effect is due to lack of proteol-
ysis, but this hypothesis is not yet well conﬁrmed experimen-
tally. We have previously demonstrated that the parental vec-
tor pJB658 can be used for high-level expression of different
bacterial proteins without the use of any signal sequences (3, 4,
31). Plasmid pJBphOx-271d and its derivatives constructed in
this study have retained the region covering Pm and rbs of
pJB658 unmodiﬁed, so the observations made here do not
seem to be related to the vector system as such. Although more
GM-CSF transcript is present when the gene is fused to a signal
sequence, the increase is not sufﬁcient to explain the vast differ-
ence in the ﬁnal protein product produced. It therefore seems
likely that the proteins are either very inefﬁciently translated in
the absence of a signal sequence or they are immediately de-
graded. Proteolytic degradation cannot be completely excluded,
but tests in a strain commonly used to reduce such problems did
not give any indication in support of degradation of the protein
product as a major reason for the low production levels.
It has been documented that secondary structures in the rbs
of mRNA can lower translation initiation efﬁciency and high
expression levels can be transferred from an N-terminal fusion
partner to a poorly expressing partner as a result of mRNA
stabilization (10, 11, 12, 27, 32). Sequence alignments show
that pelB, ompA, and CSP are only 22% and 16% identical at
the mRNA and amino acid sequence levels, respectively (Fig.
4). We analyzed the 5 ends of the different mRNAs, including
the initiation codon and its ﬂanking regions, by using the
MFOLD software (34). Interestingly, the folding energies of all
three genes tested are signiﬁcantly reduced when fused to a
signal sequence (dG values between 1 and 2 kcal) com-
pared to the energy without a signal sequence (dG values
between 4 and 10 kcal). As such, these data could possibly
partly explain the poor translation of these mRNA molecules
when not fused to a signal sequence. However, the calculated
binding energy of the optimized INF-2bS mRNA 5 end is
also low (dG values between 1 and 4 kcal), and the latter
result cannot explain why this gene is poorly expressed without
being fused to pelB. Gene expression is also controlled by the
degradation of mRNA, and in bacteria, transcription and
translation are coupled processes (27). Possibly, the up to
eightfold higher transcript levels accompanying high GM-CSF
protein levels were due to a reduced mRNA degradation
caused by high translation initiation efﬁciency and ribosomal
protection from mRNA degradation, and not so much due to
increased GM-CSF transcription rates.
In contrast with what was observed for scFv-phOx and GM-
CSF, the fusion of a signal sequence to the IFN-2b gene was
alone not sufﬁcient to achieve high level expression. It has been
previously reported that the expression of this particular gene
may be hampered due to many rare codons as well as to
secondary structure formation (1, 30, 32). This was conﬁrmed
here by the studies with the strain BL21-CodonPlus (DE3)-
RIPL, specially designed to deal with such problems, as well as
by the use of a redesigned synthetic version of the gene. In-
terestingly, a fusion signal was still needed in both cases in
order to achieve high-level expression of the gene encoding
IFN-2b. It could therefore be concluded that all three tested
genes responded similarly to the signal sequence, in spite of
their unrelatedness in terms of their primary sequences.
The three signal sequences ompA (E. coli origin), pelB (Erwinia
FIG. 4. Sequence alignments of the signal sequences pelB, ompA,
and CSP. A: mRNA sequences (5 to 3). B: Primary sequences. Iden-
tical nucleotides and residues in the DNA sequence and primary se-
quences are indicated with asterisks.
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carotovora origin), and CSP (synthetic) target their fusion part-
ners for translocation by the Sec translocase pathway (16). This
is a posttranslational pathway where the polypeptide is trans-
located in an unfolded state that is not dependent on the signal
recognition particle (13, 17). CSP was designed by us based on
its amino acid sequence (26), and it was not optimized regard-
ing formation of mRNA secondary structures. Alignments
showed that these three signal sequences share low sequence
identity at both the DNA and the amino acid sequences (Fig.
4). Thus, general sequence similarities in the signal sequences
do not seem to explain the observed effects on expression
either. Certain point mutations in the pelB coding sequence
have been shown to affect expression levels of recombinant
genes, presumably by affecting the mRNA secondary struc-
tures (5). It has been reported that codons immediately down-
stream of the translation initiation codon can have strong ef-
fects on translation initiation efﬁciency in E. coli (21, 25). We
noticed that the signal sequences pelB, ompA, and CSP all
possess the AAA triplet in position 2. This particular codon
positioned in the 2 codon of the -galactosidase coding re-
gion can cause high-level expression, but this positive effect
was highly sensitive to sequence alterations in the upstream rbs
region (29). Moreover, triplet AAA in position 2 was not
optimal for high-level expression of the enterotoxin II protein
(25), suggesting that a universal role for this codon (in that
particular location) is questionable.
Another very different type of hypothesis would be to as-
sume that the translocation process itself has an effect on the
expression rates of the corresponding protein. The Sec trans-
location apparatus consists of multiple proteins, and the trans-
location and translation processes are closely coupled (for a
review, see reference 17). The targeting of preproteins is gov-
erned by the signal sequence, and the preprotein is translo-
cated in an unfolded state. It could therefore be hypothesized
that this translocation process somehow contributes to a higher
translation rate, but to our knowledge, no experimental sup-
port of such a hypothesis has been reported.
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